FIRAT UNIVERSITY
GRADUATE SCHOOL OF NATURAL AND APPLIED SCIENCES
TÜRKİYE

ADVERSE ACTION ASSESSMENT OF IMMUNE CHECKPOINT INHIBITOR TREATMENT IN PD1 EXPRESSED NON SMALL CELL LUNG CANCER PATIENTS

Barran Yousif MIKAEEL

Master's Thesis

DEPARTMENT OF BIOLOGY

MAY, 2022

FIRAT UNIVERSITY
GRADUATE SCHOOL OF NATURAL AND APPLIED SCIENCES
TÜRKİYE

Department of Biology

Master's Thesis

ADVERSE ACTION ASSESSMENT OF IMMUNE CHECKPOINT INHIBITOR TREATMENT IN PD1 EXPRESSED NON SMALL CEL LUNG CANCER PATIENTS

Author
Barran Yousif MIKAEEL

Supervisor
Associate Prof. Dr. Abdullah ASLAN

MAY, 2022
ELAZIĞ

TÜRKİYE
FIRAT UNİVERSİTY
GRADUATE SCHOOL OF NATURAL AND APPLIED SCIENCES

Department of Biology

Master's Thesis

Title:	Adverse Action Assessment of Immune CheckPoint Inhibitor Treatment in PD1 Expressed Non Small Lung Cancer Patients
Author:	Barran Yousif MIKAEEL
Submission Date:	25.03.2022
Defense Date:	06.05.2022

THESIS APPROVAL

This thesis, which was prepared according to the thesis writing rules of the Graduate School of Natural and Applied Sciences, Fırat University, was evaluated by the committee members who have signed the following signatures and was unanimously approved after the defense exam made open to the academic audience.

		Signature
Supervisor:	Associate Prof. Dr. Abdullah ASLAN Firat University, Faculty of Science	Approved
Chair:	Prof. Dr. Orhan ERMAN Firat University, Faculty of Science	Approved
Member:	Assist. Prof. Dr. Ramazan GÜNDOĞDU Bingol University, Vocational School of Health Services	Approved

This thesis was approved by the Administrative Board of the Graduate School on
..... / ..... / 20 .....

Signature

Prof. Dr. Kürşat Esat ALYAMAÇ
Director of the Graduate School

DECLARATION

I hereby declare that I wrote this Master Degree titled “Adverse Action Assessment of Immune Check Point Inhibitor Treatment in PD1 Expressed NSCLC Patients” in consistent with the thesis writing guide of the Graduate School of Natural and Applied Sciences, Firat University. I also declare that all information in it is correct, that I acted according to scientific ethics in producing and presenting the findings, cited all the references I used, express all institutions or organizations or persons who supported the thesis financially. I have never used the data and information I provide here to get a degree in any way.

06.05.2022

Barran Yousif MIKAEEL

PREFACE

I appreciate everyone who helped me to complete this thesis from the smallest to the largest issue. Of course, above all, I sincerely thank God for giving me the ability and strength to work and for protecting me. I also want to thank my supervisor Associate Prof. Dr. Abdullah ASLAN. I am very grateful for all your continuous support and endless patience. I appreciate everyone who helped us to complete this thesis such as my family, my wife , Hiwa Hospital Staff, Assist. Prof. Dr. Goran OSMAN, Assist. Prof. Dr. Abbas B. SALIHI, DR. Farhang, Mr. Rabar QASIM, Mr.Ardalan, Dr. Seda BEYAZ, Research Assist. Ozlem GOK, and Mr. Omar JALAL helped us during preparing this study time.

Barran Yousif MIKAEEL

ELAZIĞ, 2022

TABLE OF CONTENTS

Page

ABSTRACT

Adverse Action Assessment of Immune CheckPoint Inhibitor Treatment in PD1 Expressed Non Small Cell Lung Cancer Patients

Barran Yousif MIKAEEL

Master's Thesis

FIRAT UNIVERSITY
Graduate School of Natural and Applied Sciences

Department of Biology
May 2022, Page xiii+68

There is a statistically significant between Chemotherapy mean and Immunotherapy mean especially in WBC of CBC test, urea of RFT test, and PD1 test. Lung tumor is the leading cause of tumors in global deaths, with non-small cell lung tumor accounting for roughly eighty percent of cases and having a poor prognosis. PD-1 and cytotoxic T lymphocyte-related protein four are two examples of typical co-inhibitory molecules that inhibit the immune response. Cancer cells overexpress the immunosuppressive surface ligand PD-L1, which binds to T cell molecules and inhibits T cell function. Immune checkpoint inhibitors have become more popular in cancer immunotherapy in recent years. The determination of the coefficient reflects that 14% of the HBA1C variation was determined by dose, with the remaining variation reverting to other factors influencing HBA1C. The regression coefficient for dose is 0.158, meaning one unit increase for dose will raise glucose by 0.158 via retention or current cycle. Determining the coefficient reproduces that 39% of glucose variation is determined by both cycle and dose, with the remaining variation back to other factors touching glucose. The regression coefficient for dose is 0.008, meaning one unit increase for dose will increase HBA1C by 0.008. There is no statistically significant difference in the mean of immunotherapy and chemotherapy of Thyroid function tests such as T3, T4 and TSH. Results of subgroup analysis categorized based on drugs and antibodies used to evaluate immune checkpoint inhibitors, There is no statistically significant difference between the mean of immunotherapy and chemotherapy for the electrolyte, Na, K and Cl. Finally, other tests such as glucose, HBA1C, ACE and insulin, mean immunotherapy and Chemotherapy for glucose, HBA1C, ACE and insulin serum were not statistically different. Our results suggest that suppression of PD-1 proteins is an important step in the destruction of lung cancer cells.

Keywords: Immune checkpoint inhibitor, NSCLC, PD1 protein.

ÖZET

PD1 Eksprese Edilmiş KHDAK Hastalarında Bağışıklık Kontrol Noktası İnhibitör Tedavisinin Olumsuz Etki Değerlendirmesi

Barran Yousif MIKAEEL

Yüksek Lisans Tezi

FIRAT ÜNİVERSİTESİ
Fen Bilimleri Enstitüsü

Biyoloji Anabilim Dalı
Mayıs 2022, Sayfa xiii+68

Özellikle CBC testinin WBC'si, RFT testinin üresi ve PD1 testinde immünoterapi ve kemoterapi ortalamaları arasında istatistiksel olarak anlamlı bir fark vardır.

Akciğer tümörü, vakaların kabaca yüzde sekseni için küçük hücreli olmayan akciğer tümörü muhasebesi ve kötü bir prognoza sahip olmasıyla birlikte, küresel ölümlere bağlı tümörlerin önde gelen nedenidir. PD-1 ve sitotoksik T lenfosit ile ilgili protein dört, bağışıklık tepkisini inhibe eden tipik ortak inhibitör moleküllerin iki örneğidir. Kanser hücreleri, T hücre moleküllerine bağlanan ve T hücre fonksiyonunu inhibe eden immünosupresif yüzey ligandı PD-L1'i aşırı ifade eder. İmmün kontrol noktası inhibitörleri, son yıllarda kanser immünoterapisinde daha popüler hale gelmiştir. Katsayının belirlenmesi, HBA1C varyasyonunun %14'ünün doza göre belirlendiğini ve kalan varyasyonun HBA1C'yi etkileyen diğer faktörlere döndüğünü yansıtır. Doz için regresyon katsayısı 0.158'dir, yani doz için bir birim artış, tutma veya mevcut döngü yoluyla glikozu 0.158 yükseltecektir. Katsayının belirlenmesi, glikoz varyasyonunun %39'unun hem döngü hem de doz tarafından belirlendiğini ve kalan varyasyonun glikoza dokunan diğer faktörlere döndüğünü gösterir. Doz için regresyon katsayısı 0,008'dir, yani doz için bir birim artış HBA1C'yi 0,008 arttıracaktır. T3, T4 ve TSH gibi Tiroid fonksiyon testlerinin immünoterapi ve kemoterapi ortalamalarında istatistiksel olarak anlamlı bir fark yoktur. Bağışıklık kontrol noktası inhibitörlerini değerlendirmek için kullanılan ilaçlara ve antikorlara dayalı olarak kategorilere ayrılan alt grup analizinin sonuçları, Elektrolitte, Na, K ve Cl için immünoterapi ve kemoterapi ortalamaları arasında istatistiksel olarak anlamlı bir fark olmadığını göstermektedir. Son olarak, glukoz, HBA1C, ACE ve insülin gibi diğer testler, ortalama immünoterapi ile glukoz için Kemoterapi, HBA1C, ACE ve insülin serum arasında istatistiksel fark yoktur. Elde ettiğimiz sonuçlar, PD-1 proteinlerinin baskılanmasının akciğer kanserli hücrelerin yok edilmesinde önemli bir basamak olduğunu düşündürmektedir.

Anahtar kelimeler: Bağışıklık kontrol noktası inhibitörü, NSCLC, PD1 proteini.

LIST OF FIGUERS

Page

LIST OF TABLES

Page

ABBREVIATIONS

(NSCLC) : Non-Small Cell Lung Cancer
(ALK) : Anaplastic Lymphoma Kinase
(ICIs) : Immune Checkpoint Inhibitors
(SCC) : Squamous Cell Carcinoma
(LCC) : Larger Cell Carcinoma
(MNs). : Lymph Nodes
(LNR) : Lymph Node Ratio
(OS) : Overall survival
(NCI) : National Cancer Institute
(IASLC) : The International Association for the Survey of Lung Cancer
(BIC) : Bayesian Information Criterion
(SCLC) : Small Cell Lung Cancer
(LC) : Lung Cancer
(ORR) : Objective Response Rate
(DNA) : Deoxyribonucleic
(RT) : Thoracic treatments
(SABR) : Stereotactic Ablative Body adiation
(RTOG) : Oncology Therapy Group
(PFS) : Progression-Free Survival
(IGRT) : Image-Guided Radiation Therapy
(SABR) : Stereotactic Ablative Body Radiation
(HCC) : Hepatocellular Carcinoma
(FDA) : Food Drug Administration
(USA) : United States of America
(RCC) : Renal Cell Carcinoma
(APCs) : Antigen-Presenting Cells
(CRPC) : Castrate-Resistant Prostate Cancer
(TILs) : Lymphocytes, Infiltrating Tumors
(ICI) : Immunological Control Point
(TCC) : T-lymphocytes Cytotoxic
(CBC) : Complete Blood Count
(LFT) : Liver Function Test
(AST) : Aspartate aminotrasnferase
(ALT) : Alanine Aminotransferase
(GOT) : Glutamic Oxaloacetic Transminase
(GPT) : Glutamic Pyrovic Transminase
(GGT) : Gamma-Glutamyl Transferase
(ALP) : Alkaline Phosphatase
(ACE) : Angiotensin-Converting Enzyme
(HBA1C) : Heamoglobin A1C
(INR) : International Normalized Ratio
(PT) : Prothrombin Time
(RFT) : Renal Function Test
(CKD) : Chronic Kidney Disease
(TFT) : Thyroid Function Test

(T3) : Triiodothyronine
(T4) : Thyroxine
(TSH) : Tetraiodothyronine
(HB) : Hemoglobin
(PCNA) : Proliferative Cell Nuclear Antigen
(MMP3) : Matrix Metalloproteinase 3
(TMAs) : Tissue Microarrays
(AC) : Adenocarcinoma
(SRB) : Stereotactic Radiation Body
(BWSoC) : Beatson West of Scotland Cancer Centre

1. INTRODUCTION

1.1. Back Ground of Research

Cancer is still a big hazard to human health today. Lung cancer is a major cause of tumor-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over eighty percent of cases and having a dismal prognosis [1]. The inhibition of immunological checkpoints against PD-1/PDL1 has significantly altered therapy predictions for patients with NSCLC, which is optimistic. Traditional cancer medicines primarily target cancer cells, but cancer immunotherapy tries to strengthen or restore the body's immune system's surveillance and killing of tumors [2]. The body has several immunological checkpoint molecules, all of which play a role in immune homeostasis and, eventually, immune tolerance. The immune-suppressive co-inhibitory molecules PD-1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) are two examples [3]. Cancer cells overexpress the immunosuppressive surface ligand PDL1, which binds to T cell molecules and inhibits T cell function. Immunological checkpoint inhibitors have been discovered as a result of a study into the immunological escape mechanisms of cancer cells [4].

Immune checkpoint inhibitors (ICIs) have found significant application in cancer immunotherapy in recent years. In several advanced malignancies, ICIs that target the PD-1/PD-L1 axis have demonstrated potential therapy results [5]. Anti-PDL1 antibodies durvalumab, atezolizumab, and avelumab have as well revealed anti-cancer efficacy in a variety of cancer kinds. Nonetheless, it is critical to understand that when immune system is re-energized, the body's immunological tolerance discrepancy manifests itself. Immunotherapy triggers the formation of new harmful characteristics called immune-related adverse events (irAEs) via reactivating the immune system[6]. Even though uncomplicated irAEs are uncommon, they can be deadly if not treated promptly. Furthermore, combining PD-1/PDL1 ICIs through chemotherapeutics otherwise other targeted treatments encourages appearance of contemporary hazardous responses. Raising knowledge of these adverse events (AEs) is thus crucial for improving the clinical effectiveness then safety of these novel immune-therapeutics [7].

Lung tumor is foremost reason of cancer-associated to fatalities in the United States. The mortality toll from malignancies of the respiratory system will reach one-tenth of a million. For the treatment of non-small-cell lung cancer, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) have approved numerous novel therapy regimens (NSCLC). Tumor cells are recognized via immune system, particularly T-cells, for regulator otherwise eradication based on receptors that enhance anticancer activity [8]. These cells participate in a variety of strategies that help to avoid the immunological onslaught. In various mouse tumor models, the PD-1 pathway is

one avenue for immune discharge. Manipulation of such a process may enable the immune system to eradicate malignancies [9].

Monoclonal antibodies (mAbs) have arisen as effective cancer treatment agents in a multibillion-dollar business during the last two decades. Relatlimab, Omburtamab, Etigilimab, Enoblituzumab, as well as Tiragolumab, are presently being studied as immune checkpoint inhibitors (ICIs) in medical trials [10]. The programmed cell death protein (PD-1) is a membrane protein of 288 amino acids that are generated on immune cells such as dendritic cells. Programmed death ligand 1 (PDL1), a prominent PD-1 receptor with a 40-kDa kind1 transmembrane protein, is often expressed in a wide range of cancers and is linked to tumor growth and survival [11]. When PD-1 interacts with PDL1, signals that govern T-cell mediated immunity are released. This connection guarantees that the immune system is engaged at the appropriate time, reducing the likelihood of persistent inflammation [12]. Cancer cells produce proteins such as PD-1 on their surface to deceive immune cells then avoid discovery, then this act can halt a cytolytic activity [13]. A rise in PD-1 appearance is believed to be a sign of T-cell exhaustion. Furthermore, greater PDL1 levels in NSCLC cells are related to superior efficiency of PD-1/PDL1 inhibitor remedy, according to a meta-analysis founded on randomized measured trials.

When compared to CTLA-4 inhibition, the PD-1/PDL1 pathway can produce less toxicity. Blockade utilizing monoclonal antibodies is a newly well-considered immune checkpoint inhibitor that is utilized as a therapeutic to several disorders, including malignancies of various sources. The use of antibodies to inhibit PD-1 is increasingly used to treat cancer recurrence patients. Though therapeutic targeting of the PD-1/PDL1 axis with ICIs may be more successful than standard chemotherapy, it can origin immune-related adverse effects (irAEs), most notably in digestive system, then these impacts may be systemic. Resistance to antibiotics caused by ICI blocking is assumed to be the result of cancer neoantigen development and a rise in immune checkpoint proteins unrelated to the PD-1/PDL1 axis [14].

1.2. Research Problem

Because of introduction of immune checkpoint inhibitors (ICIs), treatment of lung tumor has evolved considerably in current years. 1992 research discovered that the immunological checkpoint molecule programmed cell death-1 (PD-1) is increased during T cell death induction. Numerous immunoregulatory pathways including PD-1 have since been defined, then the effective utilize of PD-1 blockers in antitumor treatment finally led to the creation of the recent generation of ICIs. In 2014, Nivolumab became first immunotherapy drug (ICI) to be licensed for the treatment of lung tumor. Various ICIs, including pembrolizumab, atezolizumab, then durvalumab, have now been effectively introduced into clinical care and have demonstrated outstanding effectiveness. Although

the introduction of ICIs represented a significant development in lung cancer treatment, illness prognosis remains low. As a result, modern molecular-targeted therapies in combination through existing antitumor drugs then radiotherapy have newly been investigated. This study examines present state, problems, then prospects for ICI therapy in lung tumor [15].

The adverse effects of immune checkpoint inhibitors, on the other hand, are considerably distinct from those of traditional cytocidal anti-tumor treatments then molecularly targeted therapies, encompassing several organs as well as the skin and the digestive, respiratory, thyroid, then pituitary glands. These are measured adverse properties of extreme autoimmune responses, that are very rare then, when current, are typically minor, enabling continuing therapy with immune checkpoint inhibitors below careful supervision [16].

Nevertheless, managing adverse events throughout therapy needs prudence, as moderate to severe immune-connected to adverse events are linked with significantly impaired organ function then quality of life, as well as lethal effects. It is critical to creating more suitable utilization approaches, such as biomarkers and combination immunotherapy is extremely anticipated in the future [16].1.3. Layout of Thesis

The current study is divided into [5] major chapters. The first chapter contains some introductory remarks regarding the research's background, the study's difficulty, and the thesis's layout. The second chapter is a review of the literature, which includes the following sections: Introduction, Non-Small Cell Lung Cancer (NSCLC), Epidemiology of Cancer, Pathology of NSCLC, Classification of NSCLC, Therapy of NSCLC, Chemotherapy of NSCLC, Radiotherapy of NSCLC, Surgery of NSCLC, Immune Check Inhibitor (IMC), Mechanism of Immune Check Inhibitor, Drug Used as Immune Check Inhibitor. It also highlights some earlier research in this field that is relevant to this study. The third chapter covers material and method, which includes Sample Collection, Design of the Study, and a Biochemical Essay (Name of Tests)

2. LITERATURE REVIEW

2.1. General Information

Lung cancer is predicted to have caused 1.8 million new cases of cancer worldwide in 2012, or about 12.9% of all cancers [17]. In 2012, cancer will be the leading reason of death in the world, causing an appraised 1,6 million deaths (19,4%) [18]. Although lung tumors have a wide range of histology then genetic profile [19]. The majority of progress is achieved in diagnosis. A survival rate of less than 20% after five years is depressing. The histology, the diagnostic stage, and the patient's fitness determine which treatment choices are accessible for lung cancer [20]. Patients' physical, social, and emotional functioning may be adversely affected by illnesses and treatments. Patients' quality of life is not frequently assessed, although survival rates are recorded [21].

As long as lung cancer patients are not consistently monitored, value-based healthcare cannot expand. Value is defined as the health results obtained about costs [22]. America has a fast-moving transition to value, and other developed nations have had similar shifts. For this change to be successful, there must be a thorough evaluation of results to determine who and at what cost works best. To yet, there is no systematic collection of data to answer these issues. Only a few initiatives have been made to integrate quality-of-life measurements into everyday practice, then these are un-common. If present and future projects can be linked by a common worldwide standard, it would simplify implementation and create a broader global collaboration to enhance health at a reduced price point. An international working group comprised of interdisciplinary experts has been created to identify proposed outcomes for lung cancer patients, then the most suitable baseline personal, medical, and tumor features (case-mix factors) [21].

2.2. Non-Small Cell Lung Cancer (NSCLC)

Patient role in metastatic non-small cell lung cancer (NSCLC) are typically thought to be incurable. There have been a few cases when patients who were treated through a single brain or adrenal metastatic drug have had a long-term overall survival (LRT). Studies in the past, as well as personal experiences, demonstrate [23]. Most of the LRT studies were retrospective and included NSCLC patients with up to [5] metastatic sites and an OS rate of around 30%. An oligometastatic syndrome with clinical significance was first described in 1995 these patients were considered to have a metastatic possible intermediate stage then capacity profit from LRT [24]. Individuals with synchronous oligometastatic sickness (sOM) are becoming more prevalent thanks to newer, more sensitive imaging methods, which were previously thought to be rare (for example fludeoxyglucose F 18-positron discharges tomography [18F-FDG PET] [25].

In recent years, idea of treating SOM NSCLC using LRT has gained momentum. Increased therapeutic alternatives, including as less invasive surgery and stereotactic radiation therapy, have sparked continuing attention. European Society of Medical Oncology Rules Then National Comprehensive Tumor Network Rules used for 2016 and 2018 addressed SOM NSCLC as a specific therapeutic entity. There was a new M subclassification of pain established in the latest version of the TNM (8th edition) [26].

On the other hand, the M1a category was employed in patients with contralate, who had advanced survival rate than those with numerous extra thoracic metastases [26]. Further clinical studies utilizing single arms were conducted [27]. When treated with LRT, sOM NSCLC patients' progression-free survival (PFS) improved vs systemic treatment only at what time treated with LRT. As a result of first-line chemotherapy, non-progressive patients were arbitrarily assigned to receive LRT or else observation. Four-month PFS was significantly improved by four months as compared to twelve months for 48 individuals in the research by researcher [28]. It was recently reported that the middle LRT arm of OS lasted 41,2 months whereas the controller arm lasted seventeen months. With just 29 patients enrolled, the ablative stereotactic radiotherapy maintenance chemotherapy study [p 14 0,01] came to a premature conclusion [29].

SOM Due to these discoveries, NSCLC has been a popular topic of discussion at lung cancer conferences [30]. Alternative definitions and stage methods, on the other hand, were used in the clinical investigations described. According to a study was done on ClinicalTrials. in December 2018, previous clinical trials used different NSCLC definitions, and the staging procedure for categorizing oligometastatic was similarly diverse [29]. When it comes to sOM NSCLC, new techniques, such as targeted treatment and immunotherapy-based combination therapies, may now be a viable option for multimodal curative treatment options. Taxonomy unification requires uniformity in the definition of SOM NSCLCs and a required staging agreement. As a result of this agreement, inclusion criteria for clinical studies will be standardized. As a result, we tried to define SOM NSCLC through a consensus-based process. There was also a note about the proper staging procedures that should be used [30]

2.3. Epidemiology of Lung Cancer

Lung tumor is important origin of tumor-connected to death in the USA. Over the last decade, important progress has been achieved in study of non-small cell lung cancer (NSCLC). Showing through the purpose of early finding has been put in place. The nationwide lung screening study utilizing low-dose torso computed imaging in high-danger people showed twenty percentages decrease in lung tumor mortality and a 6.7 percentages reduction in general mortality. EGFR, ALK, ROS1, then NTRK affected role of numerous lines of tyrosine kinase inhibitors have also made

lung cancer more progressed. Also, immune checkpoint inhibitors (ICIs) have drastically altered countryside of non-small cell lung cancer (NSCLC) remedy. Additionally, new studies have helped us understand how these novel medications work and which patients are most likely to advantage from them, allowing us to make better decisions. As a monotherapy, ICIs are currently prescribed to patients with unresectable NSCLC who are in Phase III. As a potential biomarker for the ICI answer, programmed cell-death protein-ligand 1 expression in malignant cells has been identified. But it has a lot of drawbacks that limit its ability to discriminate in a big way Predictive indication that go beyond preset cell death protein ligand 1 expression Many concerns remain unsolved, including the right order then mixtures of these modern drugs; nonetheless, the field is stirring fast, and the general tendency is positive [31].

In the United States, lung tumor is the foremost reason of tumor-connected to death for both males then females [32]. Lung cancer is expected to kill 154,050 Americans in 2018, which is more than the next [3] utmost mutual tumors (colon, breast, then prostate)[33]. The sixty-month total survival proportion for non-small cell lung cancer (NSCLC) stays low in patient role through stage III illness, with sixty-eight percentages to 0.0 percent to ten percentages of patients through phase IVA-IVB sickness [34]. Lung cancer, of that smoking is the utmost main danger factor, has been linked to numerous environmental and lifestyle factors. 85 to 90% of lung cancers are thought to be pre-cancerous [35] Smoking and other carcinogenic substances, such as asbestos, raise the danger of developing cancer. People through a history of Hodgkin's lymphoma otherwise breast cancer are at a raised danger for lung cancer because of ionizing radiation; environmental contaminants such as tobacco smoke, radon, then metals (arsenic, chrome, then nickel); in addition to polycyclic aromatic hydrocarbons [36]. In addition to smoking, a history of lung fibrosis, HIV infection, and alcohol use were recognized as lung cancer risk factors.

In developing nations, lung cancer and lung cancer-related deaths are most common. In impoverished areas, for example Central/South America and much of Africa, lung cancer rates are predictable to be lower. Nevertheless, in several undeveloped states, a centralized reporting system is inadequate, and several cases of lung cancer are not documented, concealing the true incidence of the disease [37]. As a result of rising worldwide tobacco usage, particularly in Asia, the death rate from lung cancer is anticipated to continue to increase [38].

There has been a reduction in number of men dying from lung tumor in United States of America, but number of ladies dying from lung tumor has stayed the same from the year 2000. Despite advancements in the frequency of lung tumor in females, women's lung tumor death rates have dropped more than a decade behind men's [39]. Black men's lung cancer rates are roughly 20 percent higher than those of white men, despite the fact that lung cancer rates are falling for both races [40]. Nonetheless, Asian Americans, Pacific Islanders, and Latina females have the lowest occurrence and death rates.

Lung cancer is infrequent in those under the age of forty. From 65 to 84 years of age, it reaches its highest point. There is a median age of seventy-one years for lung cancer in the United States, then about ninety percentages of lung cancer diagnoses and fatalities occur in persons over the age of 55 [39]. In the future, lung cancer patterns will be heavily influenced by actual smoking rates. As a result (Epidemiology of NSCLC), non-smokers account for 19% of cases in the United States of America while males account for 9% [31, 41].

2.4. Pathology of NSCLC

NSCLC is categorized by a growing number of effective and customized therapies that are active in particular molecular subtypes of the disease. We must perform investigational and therapeutic study to develop next-generation medicines that may overwhelmed joint resistance mechanisms since the acquired strength of targeted inhibitors is nearly ubiquitous. In 2009, first EGFR tyrosine kinase inhibitors (EGFR TKIs) were developed, followed via second and third generations, and a fourth-generation invader is now being investigated [42]. Inhibitors of the third generation, such as Osimertinib, targeted certain mutant versions of the EGFR in a more targeted way. This new line of medications offers a number of benefits, including ability to prevent the T790M mutant EGFR protein, which discussed resistance to first- then second-cohort EGFR TKIs, then its considerably lesser sympathy used for EGFR wild-type (WT) [43]. Additionally, an increasing number of ALK fusion medications offer crucial therapeutic options for individuals who are resistant to crizotinib, a first-generation ALK TKI. Around a third of patients develop crizotinib resistance via evolving one of the rising lists of ALK-precise mutations interfering through drug binding [44]. Electronic, ceritinib, brigatinib, ensartinib, then lorlatinib are ALK TKIs of the next generation. Although these medicines have varying binding affinity in setting of distinct resistance mutations, the best patient therapy might profit from identifying the exact resistance mutation to give to the patient role the utmost suited representative to reestablish action (pathology of NSCLC) [43].

Plasma cell-free tumor DNA collection and analysis is an important tool with the potential to progress treatment results in several kinds of cancer, consisting of NSCLC. This type of assessment, that uses blood instead of tumor samples, is frequently referred to as a liquid biopsy. Molecular analysis has become more reliable because of recent technological advances, which have increased the number of tests that can be achieved on a single sample. Circulation of the tumor for both EGFR sensitization and resistance mutation testing, DNA scans are already being used in clinical practice, as are many other molecular tests, for instance the identification of struggle mutations in the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor, that is expected to be done soon. With so much new material, it was necessary for a thorough evaluation to determine

the strengths and limitations, as well as define what is now being used in clinical practice and what is still being developed. The International Association for the Survey of Lung Cancer (IASLC) has gathered together liquid biopsy then molecular pathology specialists to look at most recent indication for employing liquid biopsy in molecular analytical applications to controller the therapeutic management of progressive NSCLC patients. According to the panel, liquid biopsy methods offer a lot of potential for enhancing patient care, and they need to be used soon in a variety of NSCLC-related treatment scenarios [43].

2.5. Classification of NSCLC

NSCLC is the utmost mutual histological kind of lung tumor, accountancy for up to eighty-seven percentages of cases reported [45]. All stages of NSCLC patients have a poor overall survival rate (15 percent) [46]. and ill-fated. The tumor stage has been proved to be the best predictor of patient survival. As a result of morphology or anatomical differences, current staging criteria may not accurately represent the complexity of NSCLC. World Health Organization classification has become the norm for lung cancer morphology at this time: There are three primary kinds of NSCLC based on its morphology: Squamous cell carcinoma (SCC), larger cell carcinoma (LCC) and adenocarcinoma (ADC) . But sub kinds are very softly associated to the patient's result, then cancers with the same histological characteristics often have different clinical outcomes. When it comes to assessing lung cancer prognosis, the TNM staging system is important. The International Lung Cancer Association, the American Thoracic Society, then the European Respiratory Society have projected a modern classification for lung ADC for 2011, that incorporates numerous modifications to the earlier categorization structures. The new classification will be implemented in 2011. Despite curative resection, over a third of Phase I patients with NSCLC died from recurrent illnesses [47]. These results show a large number of high-risk individuals were missed in the early stages of TNM diagnosis. The NSCLC's categorization must be re-evaluated urgently. Some of the efforts to improve the molecular categorization of various types of cancer have already proven useful [48].

Advanced gene expression analysis methods produce detailed information that cannot be acquired only from clinical or pathologic tests. The United States of America, National Cancer Institute (NCI) delivered an encounter in December 1999: "to make cancer classification far more valuable via utilizing the abilities of comprehensive molecular analytics technologies, this contest goals at laying the foundation for shifting from morphological to molecular features of cancer classification." This study was conducted by Rami-Porta and colleagues in 2015. Several high-performance methods for gene expression evaluation have evolved in the recent thirteen years, demonstrating their ability to accurately categorize genetic expression microarrays also next-generation sequencing [46]. This research analyzes suggestions of molecular categorization on the

diagnosis, treatment, and prognosis of NSCLC patient role [49]. Non-small cell lung cancer (NSCLC) patient's role through lymph node metastases has a poor prognosis if they have this type of malignancy [50] The Asamura Group [51]. The 8th version of the TNM classification for Lung tumor has been released. A considerable improvement has been made with respect to the seventh edition of the TNM classification. There are subgroups of NSCLC patients with nodal involvement in N1 and N2 that have different prognoses, based on research findings [52]. In 2001, Ichinose et al. published their study. A mediastinal lymph node is now subdivided into N1 and N2 by the addition of the notion of skip metastasis, while in the seventh edition, "mediastinal lymph node" was defined as the anatomic site of metastatic lymph nodes (MNs). There are a few lymph node variables that must be measured while evaluating a patient's prognosis. In the TNM classification, the number of MNs is more important than their location (pN) as a predictive factor for perihilar cholangiocarcinomas, breast tumor, stomach tumor, and colorectal tumor. It is significant to note that researcher [53]. Several studies have confirmed that MNs are a predictive factor for lung cancer that is independent and non-operative [55]. According to Saji and co-workers [54]. The number of resected lymph nodes, in addition to the number of lymph node metastases, is a significant predictor of overall survival (OS) following curative resection [56]. MN and pN were shown to be weaker predictors of lymph node metastasis than the lymph node ratio (LNR), that measures degree of lymph node metastasis. (Nwogu and Colleagues, 2012). The projected effectiveness of RN, LNR, MN, and pN factors for inoperable NSCLC differed amongst studies because of diverse inpatient demographics and research goals.

The use of lymph node features for example LNR, MN, and RN in recent lymph node stages may assist physicians more correctly stage the specific lymph node of the PN1 and PN2 subgroups. The purpose of this research was to see if lymphatic node factors were connected to prognosis and the strength of the connection between these features and patient survival in NSCLC patients who had radical resection surgery. pN was likewise more successful as a predictor than the RN, MN, and LNR kinds [57]. The time from the start of process until the last test otherwise death, whichever came first, was calculated. To assess nominal data, crosstabs and the Fisher exact test were utilized. A martingale residual plot analysis of the Cox model was used to track the functional form of the study variables. Cut-offs are used to convert continuous data into categorical data. To test the kinds' ability to predict outcomes, we utilized discrimination metrics. Different patient risk categories can be identified using discrimination [58].

The AIC, Bayesian information criterion (BIC), Harrell C index, then extent underneath the curve was used to quantify discrimination in this investigation. In this research, the (AUC). The Cox proportional danger model was utilized to find important variable quantity that influence their survival. The average results are displayed with a 95% confidence interval. The Kaplan-Meier technique was utilized to construct survival curves then link them to the logo rank test. As statistical

analysis, by SPSS program 24.0 was used (SPSS). The significance has been set at P value 0.05 [58].

2.6. Therapy of NSCLC

Lung cancer is utmost mutual disease in worldwide, with an assessed 1.85 million modern cases then 1.66 million demises in 2012 [59]. Over 160,000 individuals die in the United States of America each year in 225,000 patients [60]. NSCLC records for around eighty-five percentages of wholly lung cancer cases, with the utmost joint subtypes being adenocarcinoma and squamous cell carcinomas. NSCLC treatment is highly reliant on the stage of cancer. A surgical resection is an option for about 20-25 percent of patients [61]. Patients with early-stage NSCLC will get healing treatment if it is possible. However, even after complete resection, many people are still at risk of getting lung cancer again. The five-year existence rate in resected NSCLC patient role was found to be above seventy percentages in stage I patients and just twenty-five percentages in phase IIIA patients [62]. Many resected NSCLC patients die of repeated NSCLCs, implying that many of these individuals had a micro-metastatic illness at the time of surgical resection[63]. Several studies have been showed, then some have confirmed the profits of accessary chemotherapy in improving NSCLC existence in the early phases [64]. With over two million diagnoses and a global yearly mortality rate of over 1.8 million, lung cancer (LC) is the utmost mutual oncological illness on the planet. Its financial records show that it accounts for 11.6% of worldwide morbidity and 18.4% of global death (SCLC) and non-small cell lung cancer (NCLC) are the two types of lung cancer (NSCLC). Because NSCLC is far more common than SCLC, it may be divided into two types based on histological appearance: pale and non-pale [31, 65].

NSCLC has a high-targeting rate and is closely connected to cigarette smoking. Squamous carcinomas are typically neglected in targeted treatments due to the lack of widespread drugging mutations in this tumor type [66, 67]. In Western and Asian countries, non-squamous NSCLC is the most prevalent kind of LC. Although largely-cell carcinomas are uncommon, lung adenocarcinomas are the most common non-squamous NSCLC cases. Tobacco products from the West, such as low- or moderate-tar cigarettes, have been associated to non-squamous NSCLC [68]. In many states throughout the worldwide, the dramatic decrease in cigarette utilizes over the previous several decades has resulted in a significant reduction in NSCLC-related smoking. According to certain case studies, up to half of lung adenocarcinomas patients are nowadays nonsmokers because to tobacco-induced disease reduction [69]. Because of an inoperable diagnosis or a recurrence of illness following surgery, the common of NSCLC patients are treated with systemic medicines [70]. The first ten years of the twenty-first century saw an innovation in the treatment of NSCLC, owing largely to chance discoveries. EGFR tyrosine kinase inhibitors (TKIs)

of the first generation were initially investigated in unselected NSCLCs since this receptor is overexpressed in almost all lung carcinomas. TKI-sensitizing EGFR mutations were discovered throughout the analysis of gefitinib and erlotinib responders. Crizotinib, another ground-breaking drug, was initially advanced as a MET inhibitör [71].

When ALK-activating translocations were discovered in NSCLCs, the activity toward ALK kinase was therapeutically helpful. New drug-tailored genetic alterations and medicines have been discovered as a consequence of more study [71]. Immune control inhibitors have been included in NSCLC control system, which has assisted to improve illness outcomes significantly, mainly in patient role of mutations that do not exhibit TKI sensitization [72]. Nearly a dozen molecular goals in NSCLC are now being examined in medical trials then treatment decisions are being made. The medical characteristics of NSCLC's genetic profile have been described in several recent research. However, this issue is rapidly evolving, with certain difficulties that need to be properly explored [73]. This research is intended to afford an outline of NSCLC molecular testing as it is now and, in the future [74].

2.7. Chemotherapy of NSCLC

Patients with advanced or metastatic NSCLC are given systemic therapy based on their mutational status. The epidermal growth factor mutation is the most common targetable mutation in 10–35 percent of individuals with NSCLC (EGFR). The epidermal growth factor receptor has been altered. The efficacy of EGFR tyrosine kinase inhibitors erlotinib, gefitinib, and afatinib in the treatment of progressive-phase tuber-NSCLC cancers with EGFR sensitizer mutations has been shown (such as exon nineteen and exon twenty-one L858R point mutations). The RADIANT trial was a Stage III randomized, double-blind study that investigated whether adjuvant erlotinib was beneficial. In this two-year research, 973 NSCLC patients with tumor stages IB–IIIA with EGFR protein expression or amplification were randomly assigned to erlotinib or placebo. Adjuvant erlotinib had an HR of 0.9 (95% CI 0.74–1.1; $p = 0.324$) but had no outcome on overall survival without the illness. Illness-free survival was better with erlotini in patients with EGFR-positive mutation NSCLC, through an HR of 0.53, which was not statistically significant (95 percent CI of 0.38–0.91, $p=0.039$) due to the hierarchical test technique [74, 75].

Furthermore, updated research revealed that erlotinib did not help patients with exon malignancies with exon nineteen deletions or L858R replacements, with an HR of 0.75 (ninety five percent CI 0.48–1.16). In EGFR-mutated patients in the IA-IIIA resected stage, the SELECT study is a two-year prospective Phase II adjuvant erlotinib single-arm multi-institutional experiment. A total of several hundred persons were registered, with forty five percent in Stage I, 27% in Phase II, and twenty-eight percentages in Phase IIIA [74]. The two-year free survival of disease was

ninety percentages over a three-year median follow-up (with eighty-nine patients achieving two years) (ninety-five percentages in phase I, 73 percent in phase II, and ninety-two percent in phase IIIA). After (2) years, the rate of disease-free survival was seventy two percent higher than predicted. The researchers found that whereas recurrence after discontinuing erlotinib takes an average of 8.5 months, individuals who recur have a substantially shorter treatment time than those who do not. Despite the outstanding results, caution should be used because this is a single-arm trial. Wu et al. [86] randomized patients with EGFR-activating mutations in phase-IIIA NSCLC resected to 2 years of fitinib or vinorelbine with 4-cycle cisplatin in a more recent phase-IIII study (CTONG1104). Fritinib increased disease-free survival after three years through a median follow-up of 36,5 months (range 0,1 to 62,8). (p =.013, 34% vs. 27%) The OS's discoveries haven't been made public yet, and the information is still preliminary [76]. According to the findings, adjutants' usage of current EGFR-TKIs may increase PFS but not operating system performance. The inability of EGFR-failure TKIs to eradicate the micrometastatic illness perhaps the reason for improved PFS but no improvement in OS [74].

Lung tumor is biggest basis of cancer-connected to mortality in the globe, then it is a major public health matter [77]. A total of 1,8 million modern cases are identified each year. The utmost mutual histological form is non-small-cell lung cancer (NSCLC), that accounts for eighty percentages of all cases [78]. Twenty-five percentages of persons are identified with cancer that is locally progressing and uncontrollable. For patient role through phase III NSCLC through a favorable performance status (PS) [79] concurrent chemoradiation healing through a platinum-based duplicate [80]. Can be curative. Cisplatin-etoposide, cisplatin-vinorelbine, then carboplatin-paclitaxel are three most often used chemotherapy regimens. Cisplatin-etoposide, cisplatin-vinorelbine, then carboplatin-paclitaxel are three most often used chemotherapy regimens [74, 81]. However, the finest simultaneous duplication has thus far to be found. A cisplatin-pemetrexed doublet in conjunction through radiation therapy was currently tested in the PROCLEIM study, but, the advantage of unresectable non-squamous NSCLC phase III was not demonstrated [82]. Between 60 and 66 Gray (Gy) is the optimum radiation dosage [83]. The recommended dose is optimal. Despite this harsh combination, forty percent of treated patients have a local recurrence, with metastatic diffusion occurring in one-half of cases. Several teams have tried to improve the survival rates of these in chemotherapy), notwithstanding its failure [84]. Docetaxel is a cytotoxic medication that is usually utilized in the treatment of progressive-stage NSCLC patients. This medication has a radio-sensitizing effect [85]. The weekly chemo-radiation regimen for docetaxel then cisplatin has been demonstrated to be viable in previous trials. With a similar docetaxel-cisplatin combination, a current Phase III study generated promising consequences [86].

The authors stated an optimum Objective Response Rate (ORR) (78.8 percent), DCR (96.7 percent), then medium DFS then OS (13.4 and 26.8 months) through therapies for unresectable

phase 3 NSCLC with an acceptable degree of poisonousness. For doublet docetaxelcisplatin injections, it's important to note that there was no weekly administration timetable then the radiation dose was limited to sixty Gy[87], for injections of doublet docetaxelcisplatin Only one Stage III research has looked at radiation remedy (sixty-six Gy) with severely weekly concurrent cisplatin-docetaxel medication in people with nearby progressing phase III NSCLC. With toxicity, outcome of survival was rather misleading. However, it should be emphasized that the study's subjects were entirely Asian. As a result, the results are meaningless to Caucasian inhabitants [88]. The objective of this trial was to assess how patients with phase III (IIIA or IIIB) NSCLC reacted to weekly docetaxel and platinum drug injections, as well as single radiation treatments. Due to a paucity of indication in the literature on this weekly timetable, we highlight the weekly form of the injection that agrees for a radio-sensitizing effect.

2.8. Radiotherapy of NSCLC

Cardinal lung tumor ongoings to be a source of health problems, accounting for around 30% of all cancer-related fatalities. NSCLC is the utmost mutual kind of lung cancer, accounting for more than eighty percentages of all occurrences [89]. The majority of lung cancers are detected when they have progressed to a point when they are nearby progressive or metastatic. Lung cancer incidence is lower in both males and women [90]. Despite this, NSCLC survival rates at stage IV are still 1% after 5 years. NSCLC is logically focused on median survival, and the present 5-year survival rate (60 Gy in 30 parts) is around 32,1%, despite the fact that dosage prescription has not altered over the decades [91]. It's not surprising, therefore, that new medication combinations and treatment techniques are attracting a lot of attention in order to enhance prognostications [91].

Patients with NSCLC are progressively being treated through the goal of cure rather than palliation. Patients' survival rates have enhanced in progressive stages as a result of rigorous therapies that include both systemic and thoracic treatments (RT). With surgery and systemic medications, RT has become one of the three major pillars of NSCLC treatment. By inflicting irreversible deoxyribonucleic (DNA) damage on irradiated tumor cells, RT is used in medical exercise at all stages of NSCLC sickness, for both healing and palliative drives. Patients treated with standard RT (even when chemotherapy is added) have good local tumor control, generating a surge in attention in methods for improving local treatment [92, 93]. The outcome of these patients can be improved because of recent technological advancements for example the early phases of Stereotactic Radiation Body (SBRT, IMRT) and the accompanying chemical-proton therapy of domestic progressing NSCLC stage [94]. SBRT plays an significant performance in the treatment of early-phase NSCLC, particularly in patients who are unable to endure surgery [95]. SBRT is frequently addressed in individuals who are surgical candidates[96]. In target volume delimitation,

therapy planning, and treatment, improved technology has led to enhanced efficiency and decreased local recurrence [92]. The capacity to target specific cancers while disregarding normal tissue structure, decreasing irradiation, and raising the dosage are all connected to advancements in RT. From treatment planning using fusion imaging through daily inroad replacement, image-guided radiation therapy (IGRT) plays a role in lung tumor healing. Controlling tumors then organ movements have been possible because of the creation of the 4DCT standard. The breathing movement was examined utilizing "passive" methods depend on 4DCT deliberate reconstruction pictures or "active" therapies for the patient role for breathing [92]. Metabolic imaging, dose, and adaptive methods are all important for improving accurate definition and preserving healthy tissue. MRI and functional imaging are also important in lung cancer radiation and pave the path for adaptive RT. This development in RT technology and its implications for NSCLC therapy. We will concentrate our efforts in the early years on the efficacy of BRT, the transition from 3DCRT to IMRT/VMAT, and the progress and appointment in NSCLC for proton, carbon, then MR-Lina [92].

Lung tumor is biggest source of mortality in the United Kingdom. In England and Wales in 2013, NSCLC was the utmost common kind of lung tumor (McAleese, Baluch, and Drinkwater, 2015). Following surgery, radiotherapy is the second utmost regular curative remedy for NSCLC. In the last two decades, the combination of advanced illness chemotherapy with localized disease fractionation has improved study healing rates [97]. Tuber targeting and organ prevention have benefited from technological advancements. Lung cancer results in the United Kingdom are poorer than in several other EU countries, with late-onset and low treatment rates[98]. Improved healing rates are linked to better radiation quality [99]. In a recent investigation, differing levels of access to modern radiation therapy technologies were discovered in the United Kingdom [100]. National standards are established to improve patient selection and treatment results [97]. Lung tumor moves about forty-five thousand persons in the United Kingdom each year. The mainstay of therapy for those individuals is surgical resection, that has a 5-year survival rate of about seventy percentages, even though several of them are not suitable for large operations due to frailty or cardiac respiration [101]. In the mid-1990s, a stereotatic ablative body radiation (SABR) method for thoracic cancers was launched, which delivered large doses of radiation in a fraction of the time to a small volume [102]. However, SABR has been shown to have tolerable grade 3 or 4 toxicity in peripheral lesions (12.7 percent and 3.6 percent, correspondingly), with local cancer control of about ninety percentages in 3 fractions either equivalents [102].

According to population-based research, SABR rises overall survival in older people through early-stage lung tumor [103]. In core cancers (defined as those within two cm of the proximal respiratory tree) treated through sixty Gy/3 parts, the risk of Grade 3e5 poisoning was as high as 46%. (2006, Timmerman and colleagues). According to the CHISEL study, SABR gives better

local control for early-stage malignancies than conventional radiation, underlining the need for a safe SABR dose and central cancer fractionation [104, 105]. The Stage I/II Oncology Therapy Group (RTOG) 0813 was created to do this. The dose was raised from fifty Gy in five parts to sixty Gy in the current research. In five parts, the dose was raised from 50 Gy to 5 Gy [106]. In the higher dosage arm, overall dose-limiting poisonousness was 7.2 percent, compared to 21.2 percent grade 3e5 dosage-level toxicity in the fifty Gy/5 dosage-factor [107]. The current study confirms the difference between temperately centered and ultra-central malignancies, since severe poisoning is more frequent in the ultra-central groups (PPTV) (95). NUMERIC VALUE OR SOURCE NUMBER?

According to around instructions, the biologically active dose to the cancer through an a=b ratio of ten (BED10) is one hundred Gy otherwise else higher, whereas the UK SABR consortium recommends sixty Gy/eight segments [108]. The majority of the dose and fractionation of minor central tumors has been determined by retrospective research [109]. These results are undermined by a brief follow-up with variable poisonousness and dose reporting [110]. The LungTech study (NCT01795521) planned to evaluate a sixty Gy sixty nevertheless was prematurely closed due to insufficient increase in Stage II, causing recruitment to be halted for safety reasons. The European Organization for Research and Treatment of Cancer (EORTC) is in charge of stage II [111]. In the absence of a high degree of indication, restrictive trials with comprehensive toxicity assessments are useful [102]. At Beatson West of Scotland Cancer Centre (BWoSCC), a tertiary level oncology facility with a 2.5 million people catchment region), the fifty Gy/5 fraction regimen depend on the RTOG 0813 protocol for T1-2N0M0 NSCLC has been utilized since 2013 [102].

2.9. Surgery of NSCLC

Lung cancer will affect more than 200,000 persons in the United States in 2018 [112]. Lung tumor is the foremost reason of tumor-connected to mortality in both males then ladies during globe [113]. A small percentage of patients have a limited, early-stage illness that can be treated with modality therapy, nevertheless they will likely want a multi-modern curative strategy in the future. Curator-initiated resections in patient role with progressive non-small-cell lung cancer (NSCLC) are uncommon [113]. For patient role by nearby advanced malignancies, however, treatment choices are limited and include a variety of combinations of systemic medication, radiation, and surgery. Cure is possible in ten to thirty percentages of cases of cancer at stage III (114). It's something that can be fixed. Systemic therapy is recommended for long-term survival, whereas local control can be achieved via radiation otherwise surgical excision [114]. For decades, how have mixture approaches been investigated? Immunotherapies have been altered by indication of

usage in Phase III diseases and advanced NSCLC therapy, which can boost healing choice and function even more [116].

The majority of individuals with stage IIIA NSCLC have a mediastinal node NSCLC, according to recent stage IIIA diagnoses (N2). Longer-term predictions are usually insufficient, yet exceptional outcomes are available. According to the ACSC, nodal diseases with a single-station microscopic disease are grouped together, but nodal diseases with a large, dynamic, multi-station nodal illness are divided into two groups, each with a wide variety of treatments and results [117]. In patients through IIIA N2 illness, quantity then degree of nodal engagement in therapeutic decision-making are typically more relevant than primary tumor characteristics. There has been a lot of discussion over whether or not these people should get surgery. Historically, operating cohorts have performed better than non-operating cohorts, even though most of this is attributable to improved patient selection. They've amplified their influence. There is no strong indication that adding surgery to treatment progresses survival. Opponents claim that resection improves local control rates, which are crucial for treatment. When there is little evidence and institutional and specialized prejudices are widespread, their opinions are a major determinant of medical choices. Veeramachaneni found that ninety-six percentages of surgeons recommended multimodal treatment in a low volume single station N2 scenario in a 2012 study of 513 thoracic surgeons. In the case of a patient with a substantial N2 multi-station disease, 82 percent of doctors continued to recommend surgery [117]. In a similar study, Tanner et al. polled ninety two percent of medical oncologists, although only around half of them thought resection was beneficial in setting of multi-station N2. One of the utmost significant studies to assess surgery for Phase III NSCLC is the 2009 North American Intergroup Trial (INT) 0139, which is still continuing. Patients were arbitrarily allocated to either surgical resection otherwise continuous radiation treatment, and they received concurrent chemotherapy and 45 Gy of radiation. All of the patients were given consolidation chemotherapy [117]. Overall survival was comparable in both groups (median 23.6 months for surgery versus 22.2 months for conventional treatment), but PFS was not (12.8 months versus 10.5 months) [118].

In a small retrospective one-institutional analysis, INT 0139 was found to confirm three key findings: (1) patients with thoracotomy N0 had considerably longer median OS (34.4 months vs. 26.4 months); then (2) short- then long-term pneumonectomy had poorer outcomes than lobectomy [118]. In a hotly contested post-doc research, lobectomy patients outlived matched patients, whereas pneumonectomy patients outlived matched patients. The long-term advantage is never improved, strengthening the idea that pneumonectomy is utilized when induction treatment is essential. Therapeutic induction These (2) comments have prompted a lot of discussion about Phase III activities throughout the years [117].

2.10. Immune Check Inhibitor

Lung cancer is the foremost origin of tumor death global, through a projected 1.6 million deaths in 2012 [119]. Resection is performed on the common of patients with progressive or locally unsuitable diseases. Based on data from the EUROCARE-5 study from 2000 to 2007, lung cancer has a low five-year relative survival rate when compared to other common malignancies, with a rate of 13% in Europe [120]. Because to expanded first-line, preservation, second-line, and molecular-targeted remedy, the management of patient role of progressing non-small-cell lung cancer (NSCLC) has enhanced in last decade. This leads to a development in progression-free survival (PFS), general survivorship (OS), indication management profits, then overall quality of life. General, but, the properties on five-year survival rates are minor, especially among Caucasians. The low medium and 5 -year OS highlight the crucial need for new treatments [121].

The immune system is considered to be capable of eliminating cancer that is more than a century old, according to tumor immunotherapy. In the eighteenth century, a potential connection between the immune system and tumor was found. Cooley's toxins, which killed germs, were the first vaccination to induce progressing sarcoma to regress in people who had been tumor-free for twenty-six years. Three significant results add to the increasing amount of evidence connecting cancer and the immune system. To begin with, immunocompromised people are more likely to get cancer [122]. The latter has been related to tumor remissions that arise on their own [123]. Finally, a smaller number of people who were given cytokines, such as interferon and IL-2, experienced significant responses and long-term tumor remission. Native T cells activate the adaptive immune system in NSCLC immunotherapy by stimulating pathogens or tumor cell antigens (TCs) [124]. CD4+T helper cells, which participate in antibody production, or CD8+Cytotoxic T (CTL) cells, which identify and kill antigens via cell immunity, originate from naive T cells [125]. Negative retrofits are present in T-cell activation molecular pathways that prevent T-cell over-cytotoxicity [126].

T-cell activation is controlled by CTLA-4, and the effector stage of the response is regulated by the PD-1 receptor, followed by the PD-L1 ligand. Since some medicines had previously demonstrated little therapeutic effect, the results of NSCLC immunotherapy were deceptive. CTLA-4's primary function as a negative immune regulator has been established. In the mid-1990s, it had a significant impact on the development of more effective immunotherapy drugs because of the functional blockages it caused. The CTLA-4 inhibitor ipilimumab was used in the first effective randomized controlled trials (RCTs) in advanced malignant melanoma. Ipilimumab was accepted via the FDA in 2011 [121]. Clinical studies are already underway for a variety of immunological control point inhibitors. The results of these trials will have a main influence on progressive NSCLC first-line treatment; thus, they will be known ahead of time. CTLA-4, PD-1, then PDL1 inhibitors have made important advances in NSCLC immunotherapy, according to the research. We examine

new medical studies and address difficult topics for example selecting a biomarker for immunotherapy inhibition [121].

Cancer treatment has been transformed thanks to immunotherapy coupled with monoclonal antibodies that target regulatory immunological control elements that restrict T cell activation [127]. Ipilimumab is an IgG1 fully human antibody that serves as a control point inhibitor of T-cell activation and protects T-Lymphocytes-Antigen4 (CTLA-4) from cytotoxicity. It was approved by the FDA in 2011 [128]. Both pembrolizumab and nivolumab, engineered IgG4 antibodies that prevent protein programmed death 1 (PD-1) are now accepted for therapy in progressive melanoma patients [129]. Similar medicines were eventually licensed for the treatment of insecticide-instability-high-cancers mismatch following chemotherapy therapy, in addition to non-small-cell pulmonary carcinomas [130]. Although this drug opened the way for the first tissue-agnostic biomarkers to be authorized, It was also the first time that a combination of ICPIs, ipilimumab, and nivolumab, with distinct methods of anti-carcination activity, was [131]. Lastly, the gold rush in immunotherapeutic research produced technical breakthroughs with the approval of atezolizumab, durvalumab, and avelumab as an additional ICPI for the treatment of several cancers directed against the protein programmed mortality ligand 1 (PDL1) protein [132]. In the United States of America (USA), National Food and Drug Administration (FDA) granted conditional agreement to Nivolumab and pembrolizumab as second-line treatments to hepatocellular carcinoma (HCC), an illness which substantially effects cancer progress via allowing immune evasion via the immune system [133]. Nonetheless, the primary aim of general and progression-free survival in the second-line phase-3 study of pembrolizumab vs placebo (keynote-240) was not fulfilled, according to current news. Despite the fact that over sixty immune treatment researchers have been filed in that sign, a non-specific immune system activation has identified a slew of non-specific immune-related adverse events (AEs) that can harm the liver and other vital organs [134].

The importance of detecting, preventing and treating ICPI-related adverse events to highlight the safety of hepatitis HCC immunotherapy becomes an interesting area for ICPI immunotherapy, then mutual coexistence of cirrhosis related to the liver tumor may counteract the tolerability of anti-tumor healing becomes an interesting area for ICPI immunotherapy[135]. This is especially true when the metastatic cancer treatment algorithm expands to include tyrosine kinase inhibitors derived from a variety of ICPI and ICPI-like proteins (TKI).

2.11. Mechanism of Immune Check Inhibitors

Doctors are now evaluating patients for malignancies such as breast, neck, and head tumors, in addition to progressing solid and hematological illnesses. One of the new characteristics of tumor, according to Hanahan and Weinberg[136], is the loss of immunological control, whereas

Leach et al. [137] advocated for inhibiting immune controls as a progressive tumor management strategy [137]. In 2011, the Food Drug Administration (FDA) authorized ipilimumab, a CTLA-4 anti-antibody. The (2) forms of food drug administration-accepted immunotherapy are PD-1 otherwise PDL1 inhibitors, then CTLA-4 Tcell cytotoxicity [138]. Cell-mediated immunity is carefully précised via a check-and-balance system, that involves several proteins acting as stimulators and inhibitors. CTL activation is controlled by inhibitory receptors, also known as immunological control points, that preserve auto tolerance and minimize tissue injury because of a potent immune response to infections [139]. Immunological checkpoint inhibitors for example PD-1 as well as PD-L1 may allow cytotoxic T lymphocytes to revive and fight tumor cells. The T cell receptor (TCR) of a T cell differentiates antigen in existence of a main histocompatibility complex (MHC), nevertheless inhibitor molecules reduce it via signaling stimulating factors like CD28 [140].

Immune controls for example PD-1/PDL1 as well as CTLA-4 are important mediators for tumor immune editing balance then outflow stages, according to current study. The antitumor response is suppressed if the ligands are linked to APCs or else tumor cells (PD-1-PDL1) or CTLA-4. Immunotherapy-based cancer treatments have reached a new phase in their development since monoclonal antibodies (mAbs) were targeted and inhibited. According to Hodi [140] research by Alsaab and colleagues, modern tumor immunotherapies emphasis on moving from a pro-cancer to an anticancer micro-environment, therefore improving the immune system's effective antitumor response [137]. Negative regulatory channels are also necessary. In phase 3 studies of metastatic melanoma, the monoclonal anti-CTLA4 (mAb) ipilimumab improved patients [141]. The US FDA later cleared patients with progressive melanoma to receive the treatment (USFDA). Ipilimumab was previously described as part of an early-stage trial in patient role through castrate-resistant prostate cancer (CRPC) Before being authorized by the FDA for a number of malignancies, consisting of renal cell carcinoma (RCC), melanoma, then non-small lung carcinoma (NSCLC), BMS-936558 (Nivolumab) was studied in stage 1-1b anticancer effectiveness trials [142]. Patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, multiple myeloma, or acute myeloid leukemia were administered CT 011 (palivizumab), a humanized anti-Pd-1 antibody. Finally, before FDA approval, anti-PDL1 mAb and Durvalumab displayed anticancer efficacy in a range of solid tumors. This research focuses on the PD-1 and PDL1 signaling pathways, as well as the anti-tumor immune response's negative regulatory mechanism. Preclinical research, clinical trials, and scientific developments in the treatment of different tumors using anti-PD-1 and anti-PD-L1 mAbs are also included in the study. Efforts to produce PD-1 and PD-L1 blocking combination regimens are part of traditional treatment [140].

Current study has provided a greater understanding of the factors that decrease the immune response to anti-cancer therapy, cause the finding of numerous medications that work on immune

stimulant and inhibitor pathways. The complex test molecule programmed death-1 mediates tumor-inducing immune suppression and is a great illustration of this (PD-1). The PD-1/PDL1 pathway developed physiologically to protect natural tissues from injury by reducing inflammation at antigen-expressed locations. The PD-1 protein is found on the surface of all activated T lymphocytes. When a T cell identifies an MHC complex antigen on a target cell, it produces an inflammatory cytokine, and the inflammatory process begins. These cytokines stimulate the production of tissue PDL1, which then activates the PD-1 protein on T cells, causing the immune system to lose control of inflammatory responses even in the presence of actionable antigens [143]. Overexpression of PDL1 in some malignancies, most notably in melanomas, throws this defense system into disarray. This stops the tumor's immunological response from developing. PD-1/PDL1 inhibitors work by limiting the interaction of PD-1/PDL1 proteins in the immune system, allowing the tumor to be eliminated. While PD-1/PDL1 inhibitors have proven anti-tumor effects, their effectiveness is restricted because T lymphocytes are produced to identify the tumor by anti-gene cells (APCs). If the immune response to efficient tumor cell killing is insufficient, blocking PD-1/PDL1 is ineffective. While PDL1 expression in cancers may indicate a malignancy that suppresses the immune system and so might be used as a biomarker for healing advantage, the receptiveness of all PD-L1 malignancies to PD-1/PDL1 inhibitors is not clear. PDL1-negative cancers, on the other hand, have been shown to respond to these drugs. This is still something we're working on [140].

The PD-1 protein then its ligand PDL1 play a main role in cancer growth then persistence by allowing cancers to elude immune surveillance through neutralizing them. PD-1 has been identified in monocytes, T cells, B cells, and dendritic cells, as well as lymphocytes, infiltrating tumors (TILs). PDL-1 is found in cancer then antigen-presenting cells (APCs), then it promotes cancer mass malfunction, exhaustion, neutralization, and the generation of interleukin-10 (IL-10) through interactions with T-cell PD-1 cells [144]. As a result, cancer that overexpresses PDL1 activity guards against cytotoxic (CD8+) cell death. Another interaction molecule identified on activated T cells and APCs, B7-1 (CD80), interacts through the PDL1 protein on cancer cells, resulting in a negative effector activation regulation[145]. Cancer cells become more aggressive when CD-8+ T lymphocytes are decreased, and they release a variety of proinflammatory cytokines such as cancer necrosis factor (TNF-), interleukin-2 (IL-2), and interferon Gamma (IFN-) [139, 140]. B7-1 (CD80), another interaction molecule found on activated T cells and APCs, interacts with the PD-L1 protein on cancer cells, inhibiting effector activation) [144, 145] When CD-8+ T lymphocytes are reduced, cancer cells become more aggressive and produce a range of proinflammatory cytokines for example cancer necrosis factor (TNF-), interleukin-2 (IL-2), then interferon Gamma (IFN-) [140].

The occurrence of PD-1 not only inhibits T-cell activity in the effecter, nevertheless similarly rises the conversion of the immune-suppressive Treg cell population. Although PD-1's anti-cancer immunosuppressive activities have been proven in B cells, its anti-cancer immunosuppressive effects have also been demonstrated in T cells. PD-1 expression was shown to be tightly controlled throughout B-cell development; however, it was low in pro-B cells (a precursor to mature B-cells) and increased as B-cell differentiation progressed. The macrophage protein repulsive guidance molecule B (RGMB) has recently been identified to interact with PDL2. . Although there is little evidence that PDL2 has a function in cancer immunosuppression, it has been widely investigated [140]. CTLA4 also suppresses CD4+ T effector (Teff) cells while increasing activity of Treg cells, allowing the tumor to avoid immunological detection [146] It regulates whether T cells are activated or suppressed by binding to the B7-1/2 APC protein. CTLA-4 must attach to MHC and stimulate T-cell receptor (TCR) to bind B7, that is thought to be a T-cell signaling protein [146].

Combining PD-1/PDL1 then CTLA-4/B7 axis suppression toward control tumors is an effective cancer control approach for patients with several malignancies. When T-cell (CD8+)-mediated tumor cell death is activated, PDL1 of Cancer-Recent Components, for example fibroblasts (TAM), tumor macrophages (TAM), then myeloid suppression cells, deactivates it (MDSC). Examination of T-cell surface. T-cell activity is decreased by MDSC-TAM rippling and TAM-derived IFN, leading to PD-1 then PDL1 interactions being positively controlled [140].

2.12. Drugs Used as Immune Check Inhibitors

The ability of the immune system to identify and eradicate cancer is not a novel concept [147]. Anticancer drug research, on the other hand, is causing quite a stir. Patients were recruited in about 650 studies on Clinicaltrials. in November 2017 that targeted programmed death 1 (PD-1) track any one of the ligands, compared to 225 trials in November 2015. (PDL1). Monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigens-4 also PD-(L)1 have shown impressive then long-lasting medical responses, resulting in a paradigm shift in progressive-phase tumor therapy and regulatory support for those drugs for a variety of malignant diseases [89].

CTLA-4 then PD-1 immune control point (ICI) inhibitors reduce T-cell responses in two stages, which might be harmful to the host if not managed properly. Many tumors resistant to mAbs via CTLA-4 and PD-1 reactive cancers are resistant to these inhibitory approaches, which boost tumor immunity by inhibiting particular immune receptors on activated T-cells [148]. Recent German research originate those six out of ten cases of complete or partial response (CR/PR) have been recognized, (2) are stable over time, and (2) are related to disease progression [148]. Anti-CTLA-4 and anti-PDL1 mAbs were reported to have synergistic effects in preclinical trials in melanoma, prostate tumor, and colon adenocarcinoma. When RANKL-specific mAb was

combined with ICI mAb, it improved T-cell effector function then then CD8+ T-cell infiltration, resulting in better anti-cancer immunity. fifteen, fourteen, fifteen Denosumab is routinely prescribed for patients with progressive tumor types who have bone metastases or hypercalcemia, and as a result, some patients might already be receiving denosumab in conjunction through an immunotherapy medicine without any safety issues [148]. We evaluate two kinds of cancer (advanced melanoma and non-small cell lung cancer (NSCLC)) then patient outcomes in numerous ICI trials in this work, which provides actual globe data to go beyond a published case study (ipilimumab, nivolumab, pembrolizumab). The study's specific objectives were to (1) characterize patient personal characteristics, as well as clinical and treatment features, and (2) measure general survival and medical response in these cohorts [138].

2.13. Pembrolizumab

Immune checkpoint drugs have shown to be effective against a range of cancers. Ipilimumab treatment with peptide vaccines has been authorized due to improved survival in people with metastatic melanoma (anti-CTLA-4 in this class) [141]. The PD-1 axis is the second immunological control point studied in clinical studies. After an examination of overall survival relative to conventional therapy for both illnesses (NSCLC), (2) PD-1 inhibitors, pembrolizumab, then nivolumab were accepted for the treatment of metastatic melanoma then non-small-cell lung cancer [149, 150]. In the United States, around fifty thousand individuals through metastatic melanoma otherwise NSCLC progress brain metastases each year [151]. Melanoma, in specific, frequently spreads to the brain, with a 70 percent autopsy rate. 10% of metastatic NSCLC patients acquire brain metastases after diagnosis, and another 30% have brain involvement .In both diseases, multifocal sickness is common; about half of CNS-involved individuals have more than one brain damage [152].

Most clinical studies exclude patients with untreated brain metastases, then many effective medications have not been thoroughly investigated in development for CNS penetration. Patients through any history of brain metastases are frequently omitted from trials, even if irradiation is prolonged and constant, because to possible neurological consequences [150]. Patients through untreated brain metastases are now permitted to participate in clinical trials, however, this is rare and usually requires previous test registration. Stereotactic radiation and other local therapies for brain metastases have improved survival rates [153]. Stereotactic radiation, on the other hand, can only cure a limited number of lesions and has long-term consequences. Patients through more than 4 lesions or while stereotactic radiation is not possible are treated with whole-brain irradiation, whereas bleeding, large lesions, then solitary brain metastases are usually treated with surgery [150].

Given local limitations, systemic medications may be able to help with brain metastases although also treating the extracerebral disease [154]. Concluded the well-known systemic advantage of immunotherapy in metastatic melanoma then NSCLC, we wanted to look at pembrolizumab effectiveness and safety in patients by raw or advanced brain metastases. We discuss our preliminary findings in this publication [150]. The three stages in the immune system's process of preventing and finally allowing cancer development are elimination, balance, and escape. Cancer cells (which contain antigens unique to cancer), surrounding macrophages, then stromal cells produce inflammatory cytokines, which activate, attract, and destroy cancer cells using cytotoxic systems, immunological effector cells (primarily T cells and natural killer cells), and cytotoxic systems (elimination stage). Lower immunogenic tumor cells, on the other hand, may occasionally avoid immune monitoring and spread over time (equilibrium phase). Other changes in tumor cells may also assist them to avoid detection by the host immune system (escape phase) [155]. Controlling the intensity and duration of T cell responses then maintaining self-tolerance by targeting immunological regulators is a common way for tumor cells to evade detection. T cells, natural killer cells, then convinced B cells express the PD-1 receptor, which is an immunological regulatory point. Several immunological effector and antigen-presenting cells are responsible for this. PDL1 then PDL2 are two ligands in it [155].

T-cell proliferation, cytokine production, then cytotoxic activity is all reduced while PDL1 otherwise PDL2 binds to the PD-1 signals. Cancer cells as well express PDL1 then PDL2, giving them a method to escape immune surveillance. Pembrolizumab prevents interaction amid PD-1 then PDL1 , PDL2 via binding to PD-1 Description of crystal-based structures reveals which PD-L1 also PDL2 engage with complementary-determination regions then -beads through the C D human PD-1 loop for bonding to PD-1 [155]. Pembrolizumab has a dissociation constant of 27 pm when bound to human PD-1. As a result of this interaction between PD-1 and its ligands, pembrolizumab alleviates PD-1 pathway-mediated immune response suppression as well as anticancer immune response [155]. In NSCLC, the PD-1/PDL1 signaling picture is critical. TPS lung cancer tissue samples demonstrated a high level of PDL1 expression (TPS fifty percent) in around thirty percent of patients, followed by a positive but lower level of PDL1 expression (TPS one to forty-nine percent) in the remaining patients [156]. The prognostic value of PDL1 expression in NSCLC patients has been questioned based on observational study data [157]. According to (2) recent meta-analyses, PDL1 expression in lung cancer tissues is poorly characterized [158]. Between all examinations, there was strong evidence of significant heterogeneity in Asian and non-Asian populations' research or publication. PDL1 expression, as declared later in the research, has a role in forecasting response to PD-1 pembrolizumab treatment [155].

Although various tests for PDL1 expression have been available, the PDL1 IHC 22C3 drug dx has been accepted through the Food Drug Administration and CE for utilize in Europe in the

guiding of pembrolizumab treatment (Agilent technologies [formerly Dako], CA, USA). This test using immunohistochemistry uses the monoclonal antibody 22C3 in human cancer tissue testicular, NSCLC cancers, and has high sensitivity, repeatability, then reproducibility [159]. Other tests have different features then are unlikely to produce same results. TPS is a PDL1 indicator that measures fraction of live cancer cells that have complete or else partial membrane staining through anti-PDL1 antibodies, regardless of the strength of the staining [160]. At least 100 live tumor cells should be tested, with immune cells and necrotic tissue excluded. TPS can vary from zero percent to one hundred percent and is classified by the pathologist [155]. T-cells are essential players in immune responses to infections and cancers. Antigen-precise T-cells are clonally generated and multiplied, and when stimulated with antigens, they develop effector capabilities. T-lymphocytes cytotoxic (TCC) are effector T-cells that secrete and lyse cytokines from their targets [161]. Chronic antigenic stimulation, however, can cause T-cells to lose their effector functions, even if antigens are present. T cells are unable to eliminate infections or cancerous cells because of this "exhaustion" state by the researcher [162].

T-cell proliferation and effector phase activity are limited by immune regulations, which serve as a regulatory feedback loop. They aid in the fine-tuning of the T-cell response then play a critical role in self-antigen intolerance. The prototype is CTLA4. On July 12, 2016, at 08:36, Specified [University Laval] downloaded this file. CTLA 4 binds to CD80 also CD86 on T-cells then other target cells, causing Antigen Presenting Cells (APCs) to send inhibitory signals [163]. When the TCR attaches to a major histocompatibility complex protein and its target antigen, CD80 and CD86 act as CD28 ligands, enhancing TCR signaling. CD80 and CD86 have a significantly stronger affinity for each other than CD28. As a result, CTLA4 inhibits CD28 from attaching to its ligand, lowering CD28-mediated T-cell costimulation via enhanced competitive binding to CD80 and CD86. When CTLA4 is blocked, CD80 and CD86 can bind to CD28, resulting in increased T-cell activation [162]. On the surface of receptors, there is a transmembrane protein called PD1. It is linked to two ligands: the PDL1 then PDL2 programmed cell death proteins, which both include trans-mixed proteins. Activated CD4+ and CD8+ T-cells, B-cells, macrophages, dendritic cells, then natural killer (NK) cells all display PD1 while resting lymphoid cells do not. T lymphocytes, B lymphocytes, dendritic cells, and regulatory T lymphocytes (CD4+CD25+) express PDL1. Other immune system activities may occur in addition to PD1, PDL1, and PDL2. When T cells and antigen-presenting cells are activated, PDL1 binds to CD80, providing an inhibitory signal to these cells (APC). 6 PDL2 interacts with RGMb, which sends inhibitory signals to T cells independently of PD1 [145]. Similar to the CTLA4/CD28 axis, PDL1 and PDL2 can bind to another costimulatory molecule and convert activating desires into T-cells [162].

2.14. Nivolumab

Immune regulation is concerned with membrane-bound substances that influence the "capacity" of immune responses in all cell types (B-cells, T-cells, the natural killer- cells, overpowering myeloid-derived cells, and several more). To avoid an out-of-control T-cell response, checkpoints are commonly used as brakes in the face of persistent T-cell activation. Many control points, including programmed cell death protein 1, are crucial for cytotoxic T lymphocyte protein 4 (CTLA-4) testing, according to Topalian, Drake, and Pardoll [163]. (PD1). (Finkelmeier, Trojan, and Waidmann) [164].

The idea of "loss of host immune system incidences" in tumor patients in order to (re-)create an efficient immune response against cancers was first described in the CTLA-4 proof of concept study more than two decades ago [137]. At the same time, the PD-1 molecule was introduced. T lymphocytes, in particular, express PD-1. Antigen presentation and activation of co-stimulating receptors like CD28,7 are required for naive T-cell activation. For PD1, two ligands have been discovered and identified (PDL1 or B7H1 or CD274). They were also assigned to the programmed death-ligand 2 (PDL2 or B7DC) gene. T, B, and dendritic cells generally express PDL1, whereas macrophages and dendritic cells frequently express PDL2. T-cell anergy and even death are conveyed via PD-1 then PDL1 interactions via phosphatic SHP-2 then Zap 708 inactivation, that causes T-cell anergy then death. T-cells in peripheral tissues express PD-L1, which inhibits T-cells from reacting too quickly to the effector.

Cancer cells can express PDL1, impairing the immune system's ability to react. Tumor-infiltrating lymphocytes react to antigenic tumors, generate interferon-gamma, and stimulate tumor cell growth to make PDL1, which can prevent tumor cells from activating the immune system, at least in certain circumstances [164, 165]. In important key clinical studies, patients with cancer can engage their immune system against tumor cells by aiming PD-1 or else PDL1. The discovery then development of the PD-1 cancer treatment target is discussed in detail [164]. In cancer cells, several genetic alterations occur, resulting in neoantigens that the immune system may detect. Although cancer patients have a natural immune response, it is largely ineffective in terms of tumor development prevention [136]. Tolerance induction, T-cell signaling failure, and immunological obliteration by expression of "immune control points," which generally inhibit immune responses in response to antigen stimulation, have all been revealed thus fa r[165]. Anti-PD1 immunological checkpoints have been identified for progressive lung tumors, melanoma, renal carcinoma, and other cancer forms. Some of the outcomes are as follows: This is my opinion (Gajewski, Schreiber, and Fu) [166]. The development of predictive biomarkers to distinguish non-respondent reactions then guide sickness management decisions is a particular challenge in tumor anti-PD1 research [167]. Building an efficient antitumor response and resistance mechanisms in the face of cancer

therapy [165]. Cancer Trends, vol. 1, no. 1, pp. 66-75. Trend. According to this research, IHC-directed therapy tumors had better clinical results in patients with PDL1 overexpression [168].

Even though lung tumor with a predicted PDL1 IHC may be in this category, numerous other cancers, for example melanoma and kidney cancer, have a more debatable prognosis. Furthermore, numerous problems that have yet to be resolved have hampered the use of IHC to identify PD-L1 as a predictive biomarker, including varied detecting antibodies then cutoffs, tissue preparation, biomarker consistency in original then metastatic biopsies, also cancer staining against immune cells [169]. Cancer profiling for gene expression has enabled the identification of markers of gene pregnancy then enduring assortment through a particular treatment. Recently published research looked at the link between the expression of immune-linked to genes in diverse solid cancers treated through immunotherapy [170]. An analysis of serial melanoma samples from, for instance, revealed a strong forecast for a medical response from pretreatment biopsies in those who had compound IL2 therapy [170]. In patients with pembrolizumab-treated melanoma, a profile of IFN inflammatory immune gene expression has been observed to result in higher overall response rates then progression-free survival, which has been explored further for further malignancy (PFS) [169]. Another example is stage II research using the T-Effector/IFNg signature, an eight-gen signature that indicates existing immunity, on formerly treated non-small-cell lung tumor patients. These signatures will be applied utilizing robust and reproducible genome-based approaches if they are verified. We used a combination of immune-based profiles to look at gene expression in patients with NSCLC (nonsqnSCLC), NSCLC squamous (sqNSCLC), head then neck squamous cell carcinoma (HNSCC), then skin cutaneous melanoma (SKCM). The general aim is to use immunological markers to predict PD1 checkpoint blockade response before commencing PD1 therapy, regardless of tumor type [169]. Human IgG4 (S228P), a single clonal antibody, binds to the PD-1 receptor (Programmed Death-1). Nivolumab is an anti-cancer medication (ONO-4538, MDX1106, BMS-936558) Nivolumab interacts with the protein PD-1, preventing it from interacting through its ligands, PDL1 then PDL2, as well as other proteins. PD-1, that is expressed on the surface of active T-cells when they are activated, also inhibits T-cell effector activities, i.e. [171]. The PD-1 ligands PDL1 then PDL2 are found in antigen-presenting cells for example dendritic cells, macrophages, and cancer cells. As a result, the PD-1 receptor functions as an immune control molecule in healthy people, decreasing autoimmune responses. PD-1 is a protein that is stated by cancer-infiltrating lymphocytes (TILs) Melanoma patients have high levels of these proteins. When PD-L1 in melanoma cells interacts through PD-1 in the cancer microenvironment, the immune response to the tumor is inhibited. Nivolumab has potent anti-tumor efficacy due to its unique mode of action, which involves the release of anti-tumor response inhibitors. The term Nivolumab is given to an inhibitor of an immunological control point (ICI) [172].

Activation of TCell inflammatory activity is the same mechanism that produces immune-related adverse events (IREs) associated with immunotherapy treatment. Immunotherapy side effects are caused by an immune homeostasis issue and a lack of self-antigen tolerance. The most often reported Nivolumab TRAEs, which are now classified as immune-associated ICI-treatment AEs, include dermatologic, gastrointestinal, endocrine, hepatic, renal, and pulmonary toxicity. Cardiac and neurological irAEs, on the other hand, have been described. In fact, irAE may affect practically all organs, and they are commonly referred to as days immune toxicities [172]. The words "AEs of Particular Interest," "immune-mediated adverse events," and "designated treatment-connected to adverse actions of Special Interest" were used in nivolumab prospective clinical studies. Pneumonitis, vitiligo, colitis, hepatitis, hypophysitis, then thyroid disorders are among the pharmacological side effects associated to the employment of a preset list for regulatory activities in immune-related reasons. The words (MedDRA) were first recognized [172]. When immune-related adverse events (irAEs) are encountered in clinical practice, the etiology is thought to be immune-related and inflammatory in nature[173]. Most nivolumab-related adverse events (irAEs) are minor, according to recognized criteria, and can be successfully managed with supportive care or symptomatic treatment. Most of these irAE can be reversed with treatment cessation and/or corticosteroid remedy at appropriate doses (typically (methyl)prednisolone 1-2 mg/kg) [172, 174].

On the other hand, endocrine irAE hormonal replacements, such as pituitary and thyroiditis, may be needed for the rest of one's life. Similarly, Type I diabetes (T1DM)-related autoimmune pancreatitis may need a lifetime insulin prescription [175]. There has never been a long-term prospective research of irAEs, consisting of information on patients on long-term hormone alternative treatment (thyroxine, hydrocortisone, insulin or hormonal replacement therapy) or those with musculoskeletal then rheumatic irAEs. Nivolumab's overall safety was studied in the trials CA209-003 (NCT00730639), Stage I CA209-038 (NCT01621490), Stage III CheckMate 037 (NCT01721746), and Stage III CheckMate 066 (NCT01721772) [176]. According to the treatment time known in this cohort, 312 people (54%) have previously received ipilimumab therapy. The participants in the research were given nine therapeutic dosages over the course of 3.7 month [177]. TRAE was seen in 71% of individuals who took nivolumab. Through a median follow-up period of 7.2 months, utmost public irAEs were tiredness, pruritus seventeen percentages, diarrhea thirteen percentages, and rash in 25% of patients thirteen percentages. The most common locations were nivolumab-related irAEs in forty nine percent of patients treated with cutaneous (thirty four percent) and GI (13 percent). IrAEs of grade 3 to 4 were seen in 4% of individuals. 4th grade [172]. In grade 3 irAE, five neurological sequelae have been described: dizziness, autoimmune neuropathy, central demyelination, Guillain-Barre syndrome, and involuntary muscular spasms. As a result of our efforts, a small fraction of patients (3%) stopped taking their medications, and levels of colitis, pneumonitis, alanine-aminotransferase, and lipase were found to be rising[178]. Skin-

induced (5.0 months), gastrointestinal (7.3), hepatic (7.7), lung-induced (8.9), endocrine (10.4), and renal TRAEs had median start-up durations ranging from 5.0 to 15.1 weeks (15.1). TRAEs occur in 85 percent of cases during the first 16 weeks of nivolumab treatment [172]. Except for a few long-term side effects including hypothyroidism, pituitary disease, or diabetes, virtually all nivolumab TRAEs are said to go away within a few weeks after stopping the steroid or nivolumab. Thyroid, estradiol, testosterone, fludrocortisone, and hydrocortisone should all be treated to treat endocrine irAEs, whether they are caused by thyroid, adrenal, pituitary, otherwise pituitary inadequacy [172].

Endocrine toxicity, particularly that caused by diabetic Mellitus steroids, should be avoided until a replacement dosage is provided. The GI takes 1.4 weeks, the hepatic 2.7 weeks, endocrine 3.6 weeks, also renal 4.7 weeks for a mid-grade of grades 3 and 4, whereas the cutaneous AIs take longer. There have been no fatalities linked to nivolumab monotherapy (grade 5 EIs). Nivolumab irAE progresses in direct proportion to the length of remedy. Patient role through any grade of TRAE receive a larger nivolumab dosage (median 13 vs. 7) and are treated for a longer period of time (median 6.0 vs. 2.8 months) [172]. Exposure toxicity (the number of irAEs recorded divided by total exposure length for the treatment group of patients) is not cumulative, unlike chemotherapy [141]. There are no linear relationships between Nibolumab, Nivolumab type, frequency, or severity from 0.1 to 10 mg/kg and irAE, according to Phase 1/2 data [175]. Pneumonitis was observed to have a statistically significant relationship with nivolumab dosage when 10 mg/kg was compared to 3 mg/kg (95 percent confidence interval: 1.23–6.18). When nivolumab dose levels are raised, other irAE categories do not demonstrate a significant proportional rise in irAE frequency [172].

Furthermore, clinical investigations with switched-dose nivolumab revealed that after increasing the dosage from 3 mg/kg Q2W to 480 mg Q4W Quadrant, 14.8 percent of patients with grade 3 or 4 toxicities experienced TRAEs[179]. Although no additional irAE categories were detected, the 480 mg Q4W safety data is identical to the 3 mg/kg Q2W safety data. The CA209511 (NCT02714218) 480 mg Q4W safety profile was used to assess the poisonousness profile of 142 people with unresectable or metastatic melanoma, and the CA209511 (NCT02714218) test found no new safety problems. The outcomes of these early studies corroborate the dose/exposure-safety toxicity model. In real-world data from non-clinical trials, between 10% to 12% of nivolumab monotherapy patients experienced three or four irAEs. Nivolumab's safety in patients through advanced melanoma who are being treated regularly is consistent with previous clinical trial outcomes [180]. This might be due to pre-existing conditions or fact that individuals treated outside of randomized trials were older [181]. In actual-world data, the toxicity of the nivolumab – ipilimumab combination is higher, with any IrAE grade accounting for eighty eight percent of patients, and grades three and four accounting for more than half of all patients [172, 182].

3. MATERIAL AND METHOD

Table 3.1. Table of devices

	Instrument	**Original Country**
1.	Automated Hematology analysis	Swelab Sweden
2.	Cobas Integra plus	Roch diagnosis /Germany
3.	Cobas E411	Roch diagnosis /Germany
4.	ELIZA Washer and reader	Biotech /Italian
5.	Centrifuge	Nope -Turkey
6.	Refrigerator	Nope Turkey
7.	Freezer	Turkey
8.	Shaker	Turkish
9.	Syringe 10 ml -5 ml	Turkish
10.	Gloves	Turkish
11.	Tornica	Turkish
12.	Water bath	Turkish
13.	Hematologic tube (EDTA)	Grainger -Austria
14.	Biochemistry tube (Gell tube)	Grainger -Austria
15.	Rack tube	Turkish
16.	Spectrophotometer	Germany

Table 3.2. Table of kit tests.

	Kits	Original Country
1.	Kits for determination of (TFT) (T3,T4 ,TSH) (Thyroid Function Test)	Roch diagnosis /Germany
2.	Kits for determination of (RFT)(Renal Function test)which is (Urea and Creatinine)	Roch diagnosis /Germany
3.	Kits for determination of (LFT)(Liver Function Test) which is (GOT,GPT,ALP).	Roch diagnosis /Germany
4.	Kits for determination of (Electrolyte) Which is (K+, Na+, Cl-)	Roch diagnosis /Germany
5.	Kits for determination of (HBAIC)	Roch diagnosis /Germany
6.	Kits for determination of (Glucose)	Roch diagnosis /Germany
7.	Kits for determination of hematologic test (CBC)Complete Blood Count	Swelab-Sweden
8.	Kits for determination of (Insulin)	Roch diagnosis /Germany
9.	Kits for determination of (PDI)	Biotech ELISA Italian
10.	Kits for determination of (ACE)	LTA-Italian

3.1. Sample Collection

All tests were by automated device and kits except (PD1) and (ACE) test was do it manually which is by Elisa and specterophotometer as showed in Table 3.1 and Table 3.2. Researcher received the sample of the blood by syringes of 10 ml from vein of patients of (NSCLC) (Non - Small cell lung cancer) or exist, after which put in (EDTA) tube also 7 ml put in the gel tube and EDTA tube put in the Shaker for 10 minutes also gel tube put in the room temperature until the blood will be clot after that put in the centrifuge for speeding cycle 5000 rpm for 10 minutes because of pure serum available without hemolyzing because of hemolyzing effect to the result of tests, thus (EDTA) tube investigate of complete blood count (CBC) by Swelab instrument and test of (HBA1C) by Integra instrument full automatic, tests of biochemical doing in the gel tube with put serum, such as tests of Electrolyte (Cl,K,Na) doing by Integra instrument full automatic , tests of (TFT) such as (T3,T4, TSH)tests doing by Cobas E411 instrument full automatic and test of (LFT) is (GOT ,GPT, ALP) doing by Cobas Integra tool full automatic also test of (RFT) is the test of (urea-creatinine) doing by tool of Cobas Integra full automatic and test of glucose doing by instrument of Cobas Integra full automatic, test of insulin doing by Cobas E 411 full automatic , test of (ACE) doing by spectrophotometer also procedure of this test on the below:

We have 2 reagents (R1) (R2),(R1) is phynylalanglycyglycycn 28 mm/L, and (R2) is buffer Ph 8.4 preservatives and stabilizers.

4.2 ml from (R2) put in the (R1) to make (Working reagent)

After that 0.1 ml of the serum is put in the Working reagent put in the water bath or incubator for 5 minutes from 370C after reading the first absorbance from 340 nm of wavelength afterward again put in the water bath or incubator for 5 minutes after being taken out and read second time of the same wavelength and absorbance for getting (A1) and(A2). Therefore, Calculation of A1 and A2 like this {(A2-A1)} *2588} of this calculation to get the Test of ACE.

The test of (PD1) doing by ELISA tool of the semi-auto and procedure of this on the below: PD1:

1. Regulate the wells for the dilutant standard, blank, and specimen. Prepare seven wells for the standard and one well for the blank.

2. Remove but do not wash the liquid from each well.

3. Provide 100 micrometers of detecting Regent. Fill each well with a working solution, seal the wells through the plate sealer, also incubate at 370 °C used for one hour.

4. Aspirate the solution then wash with 350 ML of 1 wash solution to each well utilizing a spray bottle multichannel Pippete, Manifold dispenser, otherwise auto washer, then let it sit for one toward two minutes. Snap plate onto absorbent paper and thoroughly wash it three times to remove any leftover liquid from all wells. After the last wash, aspirate or decant the plate, flip it over, and blot it with absorbent paper to remove any remaining wash buffer.

5. Fill each well with 100 ML of diction reagent B working solution, seal with the plate sealer, and incubate at 370 °C for 30 minutes.

6. Resume the aspiration wash procedure from step 5 for a total of 5 minutes.

7. Fill the mixing basin halfway with 90 mL of substrate solution. Incubate each well for 10-20 minutes at 370°C with the substrate solution (do not surpass 30 minutes). Avoid direct sunlight.

8. Fill each well with 50 mL stop solution. If the color shift does not look uniform, softly touch the plate to ensure complete mixing. If the color shift does not appear to be uniform, lightly touch the plate to ensure that it has been well mixed.

9. Remove any drops of water or fingerprints from the plate's bottom and check for bubbles on the liquid's surface before completing the microplate read and measurement at 450 nm directly.

3.2. Design of the Study

This research has done for 50 patients (25) patients such as used for control like received (chemotherapy) and 25 patients received of (immunotherapy) those (Pembrolizumab) (Nivolumab) but (dose) and (duration) is differentiated because of the effect of the result of the test according to the dose and duration.

For example, some of the patient the 4 weeks of the one time has received Pembrolizumab from the dose 200 mg with some of the patient 3 weeks of the one time by a dose of 168 mg. Some times for 6 weeks of one time by 400 mg that's why this dosage according to the stages has changed of the patients for example: if the stage 4 that's strong dosage doing for the patient when compared to the stage 3 or stage 2 also patient (Nivolumabish) has changed from patient to the patient according to the stage of the patient same of the patient's of (pembrolizumab) but different dosage for instance patient will receive 4 weeks of the one times different with patients has received 5 weeks of one time thus 4 weeks will receive 240 mg but for 5 weeks one time 480 mg. Therefore, most of the time the patient of the stage will be more than the dosage will increase this case happens not only in immunotherapy also in chemotherapy ha the same style happens.

3.3. Biochemical Assay (Name of the tests)

3.3.1. CBC (Complete Blood Count)

This research has done for 50 patients (25) patients such as used for control like received (chemotherapy) and 25 patients received of (immunotherapy) those (Pembrolizumab) (Nivolumab) but (dose) and (duration) is differentiated because of the effect of the result of the test according to the dose and duration. For example, some of the patient the 4 weeks of the one time has received Pembrolizumab from the dose 200 mg with some of the patient 3 weeks of the one time by a dose

of 168 mg. Some times for 6 weeks of one time by 400 mg that's why this dosage according to the stages has changed of the patients for example: if the stage 4 that's strong dosage doing for the patient when compared to the stage 3 or stage 2 also patient (Nivolumab's) has changed from patient to the patient according to the stage of the patient same of the patients of (pembrolizumab) but different dosage for instance patient will receive 4 weeks of the one times different with patients has received 5 weeks of one time thus 4 weeks will receive 240 mg but for 5 weeks one time 480 mg. Therefore, most of the time the patient of the stage will be more than the dosage will increase this case happens not only in immunotherapy also in chemotherapy the same style happens.

3.3.2. LFT (Liver Function Test) (GOT, GPT, ALP)

The liver is in charge of multiple processes, as well as primary detoxification of several toxins, protein synthesis, then enzyme manufacturing. It's situated in top right quadrant of the body, immediately below diaphragm. The liver is in charge of metabolism, RBC control, glucose production, and storage. LFTs are routinely examined using, gamma-glutamyl transferase (GGT), serum bilirubin, alkaline phosphatase (ALP), the international normalized ratio (INR), prothrombin time (PT), and albumin. These tests may assist identify liver illness, then the pattern of increase may assist form a difference diagnosis. The term "liver function testing" is deceptive because several tests are performed to determine the source of the damage rather than monitoring liver function. Excessive ALT then AST values in comparison to ALP and bilirubin indicate hepatocellular disease. A rise in ALP and bilirubin near ALT then AST indicates a cholestatic pattern. The liver's capacity to produce albumin then then vitamin K-dependent clotting factors can be utilized to evaluate its overall function [183].

3.3.3. Renal Function Test (RFT) (Urea and Creatinine)

The kidneys are responsible for removing aste and toxins such as urea, creatinine and uric acid, as well as controlling extracellular fluid volume, serum osmolality, and electrolyte concentrations and generating hormones such as erythropoietin, 1,25 dihydroxy vitamin D, and renin. The glomerulus, proximal to distal tubules, and collecting duct are all components of the nephron, or functional unit, of the kidney. Renal function testing is critical in the treatment of patients with renal disease and other disorders that decrease kidney function. Renal function tests can be used to diagnose kidney disease, assess the kidneys' response to healing, and predict the course of renal disease. Chronic kidney disease (CKD) affects around 14% of the population, according to the National Institutes of Health. The greatest frequent causes of CKD in the globe are hypertension than diabetes [184]. Renal function is a significant feature to reflect while treating patients through advanced tumors. Tumor and kidney disease are inextricably linked: chronic

kidney disease increases the hazard of obtaining tumor, then cancer patients usually have renal impairment due to age, illness-related factors, then nephrotoxic medicines. Patients with tumors are enjoying longer lives as therapies improve, potentially prolonging the time when they are vulnerable to long-term consequences. Additional symptoms, for example bone metastases or infections, whitethorn emerge and necessitate therapy. Chemotherapy, antibiotics, then other bone-targeted medications are all nephrotoxic, necessitating dosage adjustments or pauses to minimize renal damage. Nephrologists must play a significant role in the diagnosis then managing of renal impairment in cancer patients. They may be able to give kidney protection guidance while nephrotoxic drugs demand dosage reductions or pauses, as well as when novel therapy or combinations are employed. Oncologists then nephrologists' necessity work together to afford the best possible care for their patients [185].

3.3.4. Electrolyte (Na, K, Cl).

Electrolyte disorders such as hyponatremia, hypokalemia/hyperkalemia, hypercalcemia, and hypophosphatemia are frequent in individuals with cancer. Joint etiologies, which aren't confined to specific cancer types, are a common cause of such disturbances. On the other hand, electrolyte imbalances may suggest the existence of paraneoplastic activity and a bad prognosis. Furthermore, electrolyte imbalances are commonly connected with symptoms that have a poor influence on the quality of life and, as a result, can interfere with the efficiency of many chemotherapy medications. Lung tumor is the biggest reason for cancer-associated mortality globally. Lung tumor is into (2) kinds: small-cell lung cancer (SCLC) then non-small-cell lung cancer (NSCLC). Electrolyte abnormalities are more likely in the first scenario. The most common electrolyte imbalance problem in lung cancer patients is low blood sodium levels, often known as hyponatremia. Concurrent diseases, inadvertent medicines, side effects of antineoplastic therapy regimens, or the disease itself can all contribute to this condition. Even while hyponatremia is not always life-threatening, it is commonly associated with lengthier hospitalization, delays in scheduled chemotherapy, poor patient performance status, adverse treatment response, worse quality of life, and shorter survival rates.

Hyponatremia is a common complication of SCLC, and it's generally caused by an antidiuretic hormone production problem (SIADH). It's an example of dilution, where low blood sodium is connected to higher renal water retention. Only a few studies, on the other hand, exclusively address hyponatremia in individuals with NSCLC. A recent investigation of carboplatin usage in NSCLC discovered that this disease is strongly linked to the development of hyponatremia. Uncontrolled water drinking and reduced serum electrolyte concentrations might be the cause of this link. In any case, hyponatremia treatment must be tailored to the patient's specific needs, taking

into account the length and severity of sodium deficiency, as well as the underlying cause and extracellular fluid volume. The research suggests that early correction of concentration levels is important.

3.3.5. TFT (Thyroid Function Test) (T3, T4, TSH)

Thyroid function was measured in 204 lung tumor patients at the time of their initial diagnosis then compared to those through non-malignant lung illness who were age and gender-matched. Thyroid dysfunction was discovered in 67 individuals (33 percent). While low T3 levels were not related to any medical or biochemical symptoms of hypothyroidism, their short-period prognosis was lower than that of identical lung cancer patient roles with normal T3 concentrations. Three patients had primary hypothyroidism, four had low T4 concentrations also a normal free thyroxine index (FTI), and six had substantially raised thyroid stimulating hormone (TSH) with normal thyroid hormone concentrations; (9) patient roles had a high FTI through or were deprived of an increased T4 concentration as the major irregularity.

A link between thyroid function then tumor has been hypothesized meanwhile Beatson's successful treatment of a patient through metastatic breast carcinoma through oophorectomy and thyroid extract. There is a lot of indirect evidence linking thyroid function to malignant illness, notably breast cancer. Thyroid and lung tumor, in contrast, has only been documented in a few cases. A link between thyroid function then tumor has been hypothesized since Beatson's successful treatment of a lady through metastatic breast carcinoma with oophorectomy and thyroid extract. There is a lot of indirect evidence linking thyroid function to malignant illness, including breast cancer. On the other hand, thyroid disease and lung tumor and have been recorded in a small number of cases.

Overall, thyroid hormone metabolism in lung cancers favored lower T3, higher T4/T3, then self-effacingly higher 3,3′,5′-triiodothyronine (rT3) levels. The higher T4/T3 ratio was most obvious in those who had anaplastic tumors of the microscopic ("oat cell") then big cell kinds, although it did not appear to be associated to extra thoracic metastases. These findings imply that reduced T4 5′-monodeiodination alters thyroid hormone metabolism in lung tumor patients. Low T3 levels, followed by a shift in the T4/T3 ratio, might be to blame for the lowered androsterone to etiocholanolone ratio reported in lung cancers, which has been recognized as a poor predictor.

3.3.6. Glucose

Diabetes has been linked to several malignancies, including liver, colorectal, pancreatic, and breast cancer, while its effect on tumor patient outcomes is unknown. Between 2000 and 2007, we examined the electronic health records of 342 inpatients diagnosed with NSCLC and admitted to a

teaching hospital tumor center in southern Taiwan. We investigated how fasting glucose levels at the time of tumor diagnosis influenced overall survival in people with non-small cell lung cancer (NSCLC). All patients were followed up on till the end of 2010. The Kaplan-Meier method was used to compare diabetes and non-diabetic survival curves. The Cox proportional hazards model was used to compute risk ratios for the relationship between diabetes and other prognostic variables, as well as patient survival. Smoking, poor routine status, progressive phase (phase IIIB or IV), and lack of tumor-directed surgical treatment were all revealed as significant predictors of poor overall survival in NSCLC patients. Diabetes, defined as a fasting blood glucose level of 126 mg/dl, was revealed to be another independent predictor for these persons. Patients through NSCLC who had high fasting glucose levels (126 mg/dl) had a 69% greater risk of all-cause death compared to those through normal fasting glucose levels (70-99 mg/dl). Finally, diabetes was shown to be independently related through a meaningfully increased danger of all-reason mortality in NSCLC patients, demonstrating that treating diabetes or hyperglycemia efficiently may offer a chance to improve prognosis in NSCLC patients with abnormal glucose levels [186].

3.3.7. HBAIC

HbA1c (hemoglobin A1c) is a blood test that evaluates the average plasma glucose level over the past (3) months with a very little intraindividual variation. According to numerous research, high HbA1c levels are a risk factor for vascular issues in and of themselves. As a result, the amount of hypoxia in tumors in cancer patients may be connected to their HbA1c levels. Because hypoxic tumors are resistant to radiation, HbA1c levels in cancer patients who have undergone radiation are probably related to the risk of local reappearance [187].

The relationship between HbA1c levels then existence results in step III non-small cell lung tumor (NSCLC) patients preserved through radical radiation was investigated in this research. The degree of tumor hypoxia in cancer patients may be linked to hemoglobin A1c (HbA1c) levels. In this research, we looked at the link between HbA1c levels then survival results in patients through step III non-small-cell lung tumor who were given severe radiation. The medical data of 104 individuals with lung cancer who had received radiation were reviewed retrospectively. All patients' HbA1c levels were measured one week before radiation began. The effects of HbA1c levels on survival were studied. In patients through step III non-small-cell lung tumor preserved through radical radiation, pretreatment HbA1c levels are a significant predictive predictor for locoregional recurrence-free survival. Pretreatment HbA1c monitoring then stringent glycemic management possible explored to avoid locoregional reappearance in these individuals [188].

3.3.8. Insulin

Insulin has been linked to tumor formation in a variety of settings. There does not appear to be a link between insulin and non-small cell lung cancer (NSCLC). The researchers wanted to see if the PI3K/Akt (phosphoinositide 3 kinase/protein kinase B) pathway was complicated in NSCLC cell proliferation, migration, and resistance to treatment. In the absence of LY294002, a PI3K/Akt pathway inhibitor, insulin was fed to NSCLC cells [189].

Cell proliferation and drug resistance were examined using MTT wound healing and Transwell assays, as well as western blotting for cyclin A, proliferative cell nuclear antigen (PCNA), p27, matrix metalloproteinase 3 (MMP3), P GP, then proteins associated with the PI3K/Akt pathway. The current study found that insulin increased NSCLC cell proliferation, migration, and resistance to treatment. Insulin increased the expression of cyclin A, PCNA, MMP3, and P GP in NSCLC cells while decreasing the expression of p27 [190]. It was revealed which phosphor Akt expression improved in a dose-dependent way following insulin treatment. However, LY294002, a PI3K/Akt pathway inhibitor, inhibited insulin activity in NSCLC cells. As a result, the present study's findings designate that insulin contributes to the progress of NSCLC through boosting the PI3K/Akt pathway. This might cause a better comprehending of insulin's mechanism of action in NSCLC in the forthcoming [191]. Lung tumor is one of the utmost mutual tumors then the main reason of tumor death globally. Non-small cell lung cancer (NSCLC) accounts for 85 percent of all lung tumor cases, through the joint of NSCLC patient role being identified in a progressive phase. In spite of breakthroughs in NSCLC diagnosis then treatment, the five-year survival rate stays poor, ranging among ten and twenty percent. As a result, identifying important risk factors as well as developing novel treatment methods to avoid or cure NSCLC is crucial [192]. According to an earlier study, obesity is estimated to be the cause of 20% of all malignancies. Obesity has been related to type 2 diabetes, characterized by elevated insulin levels. Elevated insulin levels have been related to a raised hazard of tumor, as well as breast, pancreatic, colon then bladder tumor, according to epidemiological studies. Insulin is a powerful mitogen that has been linked to tumor development and initiation. In breast and colon cancer cells, high insulin doses stimulated pancreatic ductal cell proliferation and migration. Nonetheless, the effect of insulin on NSCLC remains uncertain [193]. The PI3K/Akt signaling pathway has been linked to non-small cell lung cancer (NSCLC), prostate cancer, and breast cancer. The PI3K/Akt signaling pathway may also be involved in cancer cell proliferation, migration, and resistance to therapy. Insulin has been demonstrated to activate the PI3K/Akt signaling pathway in breast and colon cancer cells, causing carcinogenesis. It is unknown, however, whether insulin can impact NSCLC development by activating the PI3K/Akt signaling pathway. Insulin, according to this study, promotes NSCLC cell proliferation, migration, and treatment resistance [194].

3.3.9. PD1

Lung tumor is the most joint kind of tumor and the leading reason of tumor-connected to mortality globally. NSCLC (non-small cell lung cancer) accounted for 88 % of all cases of lung illness, with common of NSCLC patients being identified at a progressive phase. In spite of advancements in NSCLC diagnosis then treatment, the 5-year survival rate stays dismal, ranging amid ten percentages and twenty percentages. As a result, identifying key risk factors and discovering novel treatment approaches to prevent or cure NSCLC are vital[194]. Tissue microarrays (TMAs) were generated from 866 NSCLC samples and used in immunohistochemistry (IHC) research. Real-time PCR assays were utilized to compare the expression levels of the CD274 (PDL1) gene in 62 NSCLC cancers to 14 normal lung tissues (RT-PCR). PD-L1 was discovered to be expressed in 32.6 percent of NSCLCs. Higher levels of PDL1 expression were associated with higher malignancy grades (G) ($p = 0.0001$), followed by lymph node status ($p = 0.0428$). In adenocarcinoma (AC) alone, patients with low PDL1 expression outlived those through high expression ($p = 0.0332$). In NSCLC, PDL1 expression is associated with greater cancer proliferation then aggressiveness, in addition to worse patient endurance, notably in the AC group.

The PDL1 receptor is found primarily in macrophages, antigen-presenting cells, B and T lymphocytes, epithelial, muscular, and endothelial cells, whereas the PD-1 receptor is found mostly inactivated cytotoxic T cells. Another goal of the study was to compare the level of PDL1 ligand expression and localization in NSCLC to that of commonly used diagnostic markers such as Ki-67 proliferation antigen, p63, and thyroid transcription factor 1 (TTF-1) proteins, which are used to differentiate morphologic subtypes of NSCLC [195]. The expression of PDL1 on the cell surface of numerous cancer cell types, especially NSCLC, is increased. This method may influence T cell interactions through target cells with antigen-presenting cells. When a PDL1 ligand quandaries to the PD-1 receptor on activated T cells, the immune system is suppressed. PDL1 often called CD274, is an immunological gatekeeper that helps the immune system inhibit cancer [196].

3.3.10. ACE

Hypertension then congestive heart failure are treated through angiotensin-converting enzyme inhibitors (ACE inhibitors). Preliminary research indicates that ACE influences both innate and adaptive immune responses. The purpose of this research is to look at how ACE inhibitors affect patients through non-small cell lung cancer (NSCLC) who are also taking PD-1/PDL1 inhibitors because no trials of ACE inhibitors in combination with ICIs have been published. We looked at NSCLC patients who had been treated through PD-1/PD-L1 antagonists in a retrospective study. There was access to clinical then co-medication therapy information, as well as tumor samples. PFS (Progression-Free Survival) for ACE medicines was 1.97 months vs. 2.56 months, p

=.01 (HR = 1.8, CI95 % 1.1–2.8). Tumors treated with ACE medication had fewer M1 macrophages, activated mast cells, NK cells, then memory-activated T cells, indicating an immunosuppressive state, according to RNA sequencing. An ACE inhibitor risied the expression of an M2 marker on the cell surface of M1-differentiating monocytes in vitro. In persons with advanced NSCLC, combining ACE medicines with PD-1/PD-L1 inhibitors appears to be related to a poor prognosis and tumor immunosuppression. These findings must be replicated in larger prospective cohorts [197].

3.4. Statistical analysis

Descriptive statistics, independent sample T test by using variance analysis in SPSS 28 (statistical analysis for social science 28), one way ANOVA, Correlation and Regression used in this study to find out the result in this research.

4. FINDINGS, AND RESULTS OF DATA ANALYSİS

4.1. Descriptive Statistics

Table 4.1. Descriptive Statistics for Demographic Questionnaire

		Frequency	Percent
Gender	Male	41	69.5
	Female	18	30.5
Age	(Mean ± SD)	(60.88 ± 10.59)	
	30-40	4	6.8
	41-50	6	10.2
	51-60	17	28.8
	61+	32	54.2
Cycle	(Mean ± SD)	5.542 ± 3.8386	
Dose	(Mean ± SD)	553.73 ± 488.67	
Duration in week	(Mean ± SD)	4.542 ± 0.8773	

Table 4.1 displays the descriptive Statistics for demographic questions. Most of the patients are male (65.5%) compared to female (30.5%). Most of the patients are aged more than 60 years of (54.2%) followed by aged 51-60 of (28.8%), 41-50 of (10.2%), and 30-40 of (6.8%) respectively. The middle age of patients are 61 years while the average of cycle. dose and duration are approximately 5, 554 and 5 respectively.

4.2. Independent Sample T Test and One Way ANOVA

Table 4.2. Independent Sample T Test between group of patients (Immunotherapy and Chemotherapy) and CBC tests

		N	Mean	Std. Deviation	t	p-value
WBC	Immunotherapy	34	8.029	5.427	-2.170	0.034
	Chemotherapy	25	14.677	16.755		
RBC	Immunotherapy	34	4.495	0.626	0.323	0.748
	Chemotherapy	25	4.440	0.679		
HGB	Immunotherapy	34	12.440	2.026	0.352	0.726
	Chemotherapy	25	12.260	1.817		
PLT	Immunotherapy	34	290.540	151.627	0.722	0.473
	Chemotherapy	25	319.339	150.961		

Table 4.2 shows there is a statistically significant difference between the mean of immunotherapy then chemotherapy for WBC test depending on (t = -2.170, p-value = 0.034). The mean of chemotherapy (14.677) is higher than the mean of Immunotherapy (8.029). On the other hand, there is no statistically significant difference between the mean of Immunotherapy and chemotherapy for RBC, HGB, and PLT because their p-values (0.748, 0.726, and 0.473) are higher than $\alpha = 0.05$ respectively.

Table 4.3. Independent sample T test between group of patients (immunotherapy and chemotherapy) and thyroid function test

		N	Mean	Std. Deviation	t	p-value
T3	Immunotherapy	34	2.149	1.839	0.159	0.875
	Chemotherapy	25	2.244	2.709		
T4	Immunotherapy	34	110.932	43.278	0.865	0.391
	Chemotherapy	25	120.624	41.531		
TSH	Immunotherapy	34	4.017	10.419	0.904	0.370
	Chemotherapy	25	2.109	1.763		

Table 4.3 shows there is no statistically significant difference between the mean of immunotherapy then chemotherapy for T3, T4, and TSH because their p-values (0.875, 0.391, and 0.370) are higher than $\alpha=0.05$ respectively.

Table 4.4. Independent sample T test between group of patients (immunotherapy and chemotherapy) and renal function test

		N	Mean	Std. Deviation	t	p-value
UREA	Immunotherapy	34	28.497	13.798	2.309	0.025
	Chemotherapy	25	38.886	20.757		
CREATININE	Immunotherapy	34	0.875	0.817	1.008	0.318
	Chemotherapy	25	1.236	1.869		

Table 4.4 shows there is a statistically significant difference between the mean of immunotherapy then chemotherapy for urea test depending on (t=2.309, p-value=0.025). The mean of chemotherapy (38.886) is higher than the mean of Immunotherapy (28.497) . On the other hand, there is no statistically significant difference between the mean of immunotherapy then chemotherapy for creatinine because its p-value (0.318) is higher than $\alpha=0.05$.

Table 4.5. Independent sample T test between group of patients (immunotherapy and chemotherapy) and liver function test

		N	Mean	Std. Deviation	t	p-value
AST	Immunotherapy	34	27.618	20.469	1.475	0.146
	Chemotherapy	25	37.700	31.994		
ALT	Immunotherapy	34	28.059	25.540	0.599	0.522
	Chemotherapy	25	31.736	19.834		
ALP	Immunotherapy	34	100.676	53.292	1.899	0.063
	Chemotherapy	25	150.360	139.709		
TSB	Immunotherapy	34	0.565	0.719	0.935	0.354
	Chemotherapy	25	0.782	1.070		
BILD	Immunotherapy	34	0.171	0.091	1.255	0.215
	Chemotherapy	25	0.260	0.403		

Table 4.5 shows there is no statistically significant difference between the mean of immunotherapy and chemotherapy for AST, ALT, ALP, TSB, and BILD because their p-values (0.146, 0.522, 0.063, 0.354, and 0.215) are higher than α=0.05 respectively.

Table 4.6. Independent sample T test between group of patients (immunotherapy and chemotherapy) and electrolyte

		N	Mean	Std. Deviation	T	p-value
Na	Immunotherapy	34	142.971	18.491	1.296	0.201
	Chemotherapy	25	138.080	4.102		
K	Immunotherapy	34	3.968	0.825	1.209	0.232
	Chemotherapy	25	8.064	19.797		
Cl	Immunotherapy	34	101.147	12.216	0.920	0.361
	Chemotherapy	25	97.364	19.315		

Table 4.6 shows there is no statistically significant difference between the mean of Immunotherapy and Chemotherapy for NA, K and CI because their p-values (0.201, 0.232, and 0.361) are higher than α=0.05 respectively.

Table 4.7. Independent sample T test between group of patients (immunotherapy and chemotherapy) and other test

		N	Mean	Std. Deviation	t	p-value
Glucose	Immunotherapy	34	126.600	47.504	1.502	0.139
	Chemotherapy	25	148.076	62.401		
HBA1C	Immunotherapy	34	1.688	2.391	1.020	0.312
	Chemotherapy	25	1.156	1.206		
PD1	Immunotherapy	34	21.804	26.817	3.580	0.001
	Chemotherapy	25	1.816	8.830		
ACE	Immunotherapy	34	38.906	23.445	0.761	0.540
	Chemotherapy	25	34.492	19.887		
Insulin Serum	Immunotherapy	34	29.185	36.298	1.916	0.060
	Chemotherapy	25	14.392	15.089		

Table 4.7 shows there is a statistically significant difference between the mean of ımmunotherapy then chemotherapy for PD1test depending on (t=3.58, p-value=0.001). The mean of chemotherapy (1.816) is less than the mean of Immunotherapy (21.804) as shown in Figure 4.1. On the other hand, there is no statistically significant difference between the mean of immunotherapy then chemotherapy for Glucose, HBA1C, ACE and insulin serum because their p-values (0.139, 0.312, 0.540, also 0.060) are higher than α=0.05 respectively.



Figure 4.1. Shows the mean difference between immunotherapy and chemotherapy group for PD1 test

4.3. Correlation and Regression Immunotherapy

The weak negative correlation between the independent variable (dose) then the dependent variable is seen in Table 4.8. (K). Subsequent the detection of a weak negative link between (dose tests) then (K) (0.49) via Pearson's correlation analysis, it is critical to comprehend the forecast and effect rate of dose on K. The same table also displays the ANOVA table for determining the goodness of fit for the explanatory variable (dose) on the response variable (K), signifying that the model is suitable (F=9.862 and P-Value =0.004). The outcomes of constant, Slope, t-value, then coefficient of determination are shown in the table above (R Square). The Regression Coefficient (B) for dose is -0.003, that recommends that raising dose by one unit reduces K by 0.003. The coefficient of determination (R Square) describes how much variation in the dependent variable may be described through the independent variable. The coefficient of determination (R2) displays that dose accounts for 24% of the variance in K, through the rest variation due to other variables that affect K.

Table 4.8. Forward multiple regression analysis between independent variables (dose, cycle, duration in week) and dependent variable (K)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	5.054	13.737	0.001	-0.490	0.240	9.862	0.004
Dose	-0.003	-3.141	0.004				

Table 4.9. Forward Multiple Regression Analysis between independent variables (dose, cycle, duration in week) and dependent variable (glucose)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	47.980	2.225	0.033	0.620	0.390	9.514	0.001
Cycle	5.535	3.619	0.001				
Dose	0.158	2.684	0.012				

Table 4.9 depicts the slight positive association between the independent factors (dose and cycle) then the dependent variable (glucose). Subsequent the finding of a weak positive link amid (dose then cycle) and (glucose) (0.62) via Pearson's correlation analysis, it is critical to comprehend the guess then effect rate of either dose and cycle on glucose.

The same table also provides the ANOVA table for evaluating the quality of fit for the explanatory factors (dose and cycle) on the response variable (glucose), demonstrating that the model is suitable (F=9.514 and P-Value =0.001).

The outcomes of constant, Slope, t-value, and coefficient of determination are shown in the table above (R Square). Cycle's Regression Coefficient (B) is 5.535, which implies that raising one

unit for cycle would increase glucose by 5.535 when maintaining or increasing dose. The Regression Coefficient (B) for dose is 0.158, that indicates that raising one unit for dose will rise glucose via 0.158 if the cycle is held constant. The coefficient of determination (R Square) describes how much variation in the dependent variable may be described via the independent variable. The coefficient of determination (R2) displays that 39 percent of the variance in glucose is determined by both cycle and dose, with the remaining variation due to other variables that disturb glucose.

Table 4.10. Forward multiple regression analysis between independent variables (dose, cycle, duration in week) and dependent variable (HBA1C)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	-0.747	-0.661	0.513	0.380	0.140	5.258	0.029
Dose	0.008	2.293	0.029				

The modest positive association between the independent variable (dose) and the dependent variable is seen in Table 4.9. (HBA1C). Subsequent the detection of a modest positive link among (dose) also (HBA1C) (0.38) by Pearson's correlation analysis, it is critical to comprehend the forecast then effect rate of dose on HBA1C. The same table also displays the ANOVA table for determining the goodness of fit for the explanatory variable (dose) on the response variable (HBA1C), demonstrating that the model is suitable (F=5.258 and P-Value =0.029).

The outcomes of constant, Slope, t-value, then coefficient of determination are shown in the table above (R Square). The Regression Coefficient (B) for dose is 0.008, that recommends that raising dose by one unit raises HBA1C by 0.008. The coefficient of determination (R Square) describes how much variation in the dependent variable can be explained by the independent variable. The determination of Coefficient (R2) shows that dose accounts for 14 percent of the variation in HBA1C, through the rest variation due to other variables that affect HBA1C as in Table 4.10 show.

4.4. Immunotherapy and Chemotherapy

Table 4.11. Forward multiple regression analysis between independent variables (Dose, Cycle, Duration in week) and dependent variable (WBC)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	5.090	2.349	0.022	0.430	0.180	12.454	0.001
Dose	0.010	3.529	0.001				

Table 4.11 show us there is a statistically significant in WBC of CBC test.

Table 4.12. Forward multiple regression analysis between independent variables (dose, cycle, duration in week) and dependent variable (urea)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	25.449	7.763	0.000	0.370	0.140	9.118	0.004
Dose	0.013	3.020	0.004				

In Table 4.12 show ıt thats there is statistically significant in urea test of RFT test.

Table 4.13. Forward multiple regression analysis between independent variables (dose, cycle, duration in week) and dependent variable (glucose)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	113.761	9.302	0.000	0.280	0.080	4.736	0.034
Cycle	3.958	2.176	0.034				

In Table 4.13 there is no have statistivally significant in glucose test.

Table 4.14. Forward multiple regression analysis between independent variables (dose, cycle, duration in week) and dependent variable (PD1)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	20.157	4.500	0.000	-0.260	0.070	4..097	0.048
Dose	-0.012	-2.024	0.048				

Table 4.15. Simple linear regression analysis between independent variables (PD1) and dependent variable

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	1.412	3.909	0.001	0.49	0.25	10.273	0.003
PD1	0.034	3.205	0.003				

Table 4.14 and Table 4.15 displays the modest negative and positive correlation between the independent variable (PD1) then the dependent variable (PD2) (T3). Subsequent the detection of a modest positive association between (PD1) then (T3) (0.49) via Pearson's correlation analysis, it is critical to understand the prediction and effect rate of PD1 on T3. The same table also displays the ANOVA table for determining the goodness of fit for the explanatory variable (PD1) on the response variable (T3), demonstrating that the model is suitable (F =10.273 and P-Value =0.003).

The outcomes of constant, Slope, t-value, and coefficient of determination are shown in the table above (R Square). The Regression Coefficient (B) for PD1 is 0.034, that recommends that raising PD1 by one unit increases T3 by 0.034.

The coefficient of determination (R Square) describes how much variation in the dependent variable may be described via the independent variable. Determination of Coefficient (R2) displays that PD1 accounts for 25% of the variation in T3, through the remainder accredited to other variables that effect T3.

Table 4.16. Simple linear regression analysis between independent variables (PD1) and dependent variable (Na)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	134.846	38.384	0.000	0.54	0.3	13.202	0.001
PD1	0.373	3.633	0.001				

Table 4.16 displays the modest positive correlation between the independent variable (PD1) then the dependent variable (PD2) (T3). Subsequent the detection of a modest positive association between (PD1) then (T3) (0.49) via Pearson's correlation analysis, it is critical to understand the prediction and effect rate of PD1 on T3.

The same table also displays the ANOVA table for determining the goodness of fit for the explanatory variable (PD1) on the response variable (T3), demonstrating that the model is suitable (F=10.273 and P-Value =0.003). The outcomes of constant, Slope, t-value, and coefficient of determination are shown in the table above (R Square). The Regression Coefficient (B) for PD1 is 0.034, that recommends that raising PD1 by one unit increases T3 by 0.034. The coefficient of determination (R Square) describes how much variation in the dependent variable may be described via the independent variable. Determination of Coefficient (R2) displays that PD1 accounts for 25% of the variation in T3, through the remainder accredited to other variables that effect T3.

Table 4.17. Simple linear regression analysis between independent variables (PD1) and dependent variable (K)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	4.332	27.687	0.000	-0.54	0.31	13.391	0.001
PD1	-0.017	-3.659	0.001				

Table 4.17 depicts the weak negative correlation between the independent variable (PD1) then the dependent variable (PD2). (K). Subsequent the identification of a modest negative link

between (PD1) then (K) (0.54) via Pearson's correlation analysis, considerate the prediction then impact rate of PD1 on K is crucial. The same table has an ANOVA table for testing the goodness of fit for the explanatory variable (PD1) on the response variable (K), suggesting that the model is appropriate (F=13.391 and P-Value =0.001).

The table above displays the findings of constant, Slope, t-value, and coefficient of determination (R Square). The PD1 regression coefficient (B) is 0.017, implying that increasing one unit of PD1 decreases K by 0.017.

The coefficient of determination (R Square) describes how much variation in the dependent variable may be clarified via the independent variable. Determination of Coefficient (R2) displays that PD1 accounts for 31% of the variance in K, through the rest variation due to other variables that effect K.

Table 4.17 depicts the weak negative correlation between the independent variable (PD1) then the dependent variable (PD2). (K). Subsequent the identification of a modest negative link between (PD1) then (K) (0.54) via Pearson's correlation analysis, considerate the prediction then impact rate of PD1 on K is crucial. The same table has an ANOVA table for testing the goodness of fit for the explanatory variable (PD1) on the response variable (K), suggesting that the model is appropriate (F=13.391 and P-Value =0.001). The table above displays the findings of constant, Slope, t-value, and coefficient of determination (R Square). The PD1 regression coefficient (B) is 0.017 implying that increasing one unit of PD1 decreases K by 0.017. The coefficient of determination (R Square) describes how much variation in the dependent variable may be clarified via the independent variable. Determination of Coefficient (R2) displays that PD1 accounts for 31% of the variance in K, through the rest variation due to other variables that effect K.

Table 4.18. Simple linear regression analysis between independent variables (PD1) and dependent variable (Insulin Serum)

	Coefficients			Summary		ANOVA	
	B	T	P-value	Corr.	R2	F	P-value
(Constant)	18.664	2.437	0.021	0.36	0.13	4.66	0.038
PD1	0.483	2.159	0.038				

In Table 4.18 there is no statistically significant in insülin serum test because theire P-value are more than 0.005.

Table 4.19. Independent sample T test between normal and abnormal results of PD1 and all tests (WBC, RBC, HGB, PLT, T3, T4, TSH, urea, creatinine, AST, ALT, ALP, TSB, BILD, Na, K, Cl, glucose, HBA1C, ACE and insülin serum

		N	Mean	Std. Deviation	t	p-value
WBC	Normal	29	7.184	3.562	-2.328	0.026
	Abnormal	5	12.929	10.909		
RBC	Normal	29	4.429	0.639	-1.502	0.143
	Abnormal	5	4.876	0.398		
HGB	Normal	29	12.383	2.006	-0.393	0.679
	Abnormal	5	12.773	2.351		
PLT	Normal	29	308.855	155.685	1.747	0.090
	Abnormal	5	184.310	58.915		
T3	Normal	29	2.279	1.955	0.898	0.303
	Abnormal	5	1.398	0.558		
T4	Normal	29	110.579	41.990	-0.113	0.911
	Abnormal	5	112.980	55.712		
TSH	Normal	29	4.010	11.123	-0.009	0.968
	Abnormal	5	4.058	5.438		
UREA	Normal	29	27.997	14.595	-0.504	0.618
	Abnormal	5	31.400	8.204		
CREATININE	Normal	29	0.882	0.881	-0.119	0.906
	Abnormal	5	0.834	0.262		
AST	Normal	29	25.928	20.390	-1.166	0.252
	Abnormal	5	37.420	20.137		
ALT	Normal	29	28.579	26.811	0.282	0.780
	Abnormal	5	25.040	18.344		
ALP	Normal	29	98.828	51.613	-0.481	0..633
	Abnormal	5	111.400	67.929		
TSB	Normal	29	0.572	0.762	0.148	0.883
	Abnormal	5	0.520	0.444		
BILD	Normal	29	0.179	0.094	1.371	0.180
	Abnormal	5	0.120	0.045		
Na	Normal	29	142.897	20.035	-0.055	0.956
	Abnormal	5	143.400	3.286		
K	Normal	29	3.910	0.878	-0.126	0.901
	Abnormal	5	4.300	0.255		
Cl	Normal	29	100.379	13.045	-0.880	0.366
	Abnormal	5	105.600	3.286		
Glucose	Normal	29	126.945	48.341	0.101	0.921
	Abnormal	5	124.600	47.468		
HBA1C	Normal	29	1.639	2.430	-0.282	0.761
	Abnormal	5	1.969	2.389		
ACE	Normal	29	39.259	24.921	0.208	0.836
	Abnormal	5	36.860	13.458		
Insulin Serum	Normal	29	31.745	38.172	0.990	0.330
	Abnormal	5	14.340	18.616		

Table 4.19 shows there is a statistically significant difference between mean of normal then abnormal outcomes of PD1 and WBC test depending on (t=-2.328, p-value=0.026). The mean of abnormal (12.929) is higher than the mean of normal (7.184).

On the other hand, there is no statistically significant difference between the mean of normal and abnormal results of PD1 and all other remaining tests.

5. RESULT AND DISCUSSION

In this experimental shows, there is a statistically significant difference among the mean of immunotherapy and chemotherapy for WBC test depending on (t=-2.170, p-value=0.034) The mean of chemotherapy (14.677) is higher than the mean of immunotherapy (8.029) and CBC tests. On the other hand, there is no statistically significant difference between mean of immunotherapy through chemotherapy for RBC, HGB, and PLT because their p-values (0.748, 0.726, and 0.473) are higher than α=0.05 respectively. According to Rojko et al [198]. We analyzed 352 and 466 patients from sub cohorts with brain and bone metastases. The control group composed of 168 individuals with no clinically identifiable distant metastases. In an observational study of hematological parameters in patients with progressive lung tumor, absolute lymphocyte count was significantly lower than the significantly higher absolute lymphocyte count (ANC: P 0.001) in all patient subgroups, regardless of histopathology. (ALC: P 0.001) was discovered. Type or metastatic site. Surprisingly, patients with brain metastases showed an increasing trend in platelet counts (P 0.001), while patients through bone metastases displayed a significantly increasing downward trend (P = 0.043).

Patients who develop overt thyroid dysfunction with therapy had substantially greater overall survival (HR = 0.18 [95 percent CI: 0.040,76]; p = 0.020) than significantly higher progression-free survival (PFS). It was high (HR = 0, 39 [0,150,998]; p = 0.050). The one-year OS rate is 94 percent vs. 59 percent, and the one-year PFS rate is 64 percent vs. 59 percent compared to patients who did not have thyroid dysfunction). Patients with ATAb levels above the median have median ATAb levels throughout therapy, with a 1-year OS rate of 83% vs. 49% and a PFS rate of 54% vs. 20%. Patients with persistent ATAb levels above the median had greater OS (HR = 0.41 [0.190,89], p = 0.025) and PFS (HR = 0.54] than individuals. 0.310.95, p = 0.032)) was high. Chronic ATAb levels are lower than the median. Patients with ATAb levels above the head median during therapy have median levels. On the other hand, compared to our research of thyroid function test, there is no statistically significant difference in the mean of immunotherapy then chemotherapy for Thyroid Function Test such as T3(Triiodothyronine), T4 (Thyroxine), and TSH (Thyroid-stimulating hormone) since their p-values (0.875, 0.391, and 0.370, respectively) are more than =0.05. Magari et al. [2020] included 112 patients (G1 = 87 P, G2 = 25 P) in their research. At 12 months, mean GFR dropped by 28.4 mL/min/1.73 m2 (22.3 percent, p = 0.001) with G1 and 13.8 mL/min/1.73 m2 (17.2%, p = 0.001) with G2. The median survival period for patients in G1 was 9.6 months (1,152.4), whereas it was 19.7 months in G2 (3,756.9). At the time of analysis, GFR of 6089 mL/min/1.73 m2 increased overall survival (p = 0.003) and a high cumulative pemetrexed dosage of (p = 0.003) compared to cisplatin (p = 0.001). It was mostly connected to = 0.04.

On the other hand, the renal function test of our research shows a statistically significant difference among the mean of immunotherapy then chemotherapy for the urea test depending on (t=2.309, p-value=0.025). Table 4.4 reveal that the mean of chemotherapy (38.886) is greater than the mean of immunotherapy (28.497). Also, there is no statistically significant difference between the mean of immunotherapy then chemotherapy for creatinine because its p-value (0.318) is higher than α=0.05. In the literature, survival rates for patients with progressive otherwise metastatic NSCLC using cisplatin-pemetrexed as first-line treatment fluctuated among seven then twelve months, comparable to those seen in this study. increase. However, treatment with cisplatin is increasingly carefully recommended because it can adversely affect kidney function. More than 70% of patients developed renal dysfunction after the first dose, which was irreparable in some cases. Acute cisplatin intoxication is associated with intracellular gathering that stimulates activation of several signaling pathways (MAPK, p53, ROS, TNF ...) and ultimately causes tubule cell death [41]. The physio-pathological origins of long-term cisplatin toxicity remain unclear. The chemical's active form, free cisplatin, is removed not only via glomerular filtration as well as by tubular secretion. Twenty to thirty-five percent of highly vascularized cisplatin is originate in urine, then free cisplatin approval is related to creatinine approval in individuals. Recommendations from 2008 aided in lowering the incidence of acute renal disappointment by 5 to 10% [200].

According to Kim, Cho, and Yoo [201], the median overall survival (OS) of all patients was 31.1 (95 percent CI = 3.558.7) months, with OS rates of 63.6 percent then 24.2 percent, correspondingly, at years one then two. Patients aged 65 and under had median OS rates of 45.2 (ninety five percent CI = 13.576.9) then 19.5 (ninety five percent CI = 7.131.8) months, correspondingly (P =.189). Patients who had WBCT for more than forteen days but less than 28 days had a median OS of 16.2 (95 % confidence CI = 13.319.2) months and those who received WBCT for more than 14 days but less than 28 days had a median OS of 45.2 (ninety five percent CI = 14.476.0) months, correspondingly (P =.437). The median OS rates for patients who had previously received conservative remedy were 45.2 (ninety five percent confidence CI = 9.181.3) and 3.9 (ninety five percent CI = unable to compute), correspondingly (P =.00000). Patients through squamous cell carcinoma (SCC) had 5.6 (ninety five percent CI = unable to calculate) as well as 45.2 (95 percent CI = 9.181.3) months of median OS, correspondingly (P =.262). The median OS rate for patients through ECOG PS 3 was 14.3 months (95 percent CI = 8.819.8) months; the percentage for patients without ECOG PS 3 was unknown. The mean OS rates for patients with ECOG PS 3 then those without were 85.7 (ninety five percent CI = 58.4113.0) then 12.7 (ninety five percent CI = 8.516.9) months, correspondingly. (P =.000). There were no thoughtful contrary possessions encountered.

In contrast, in our research, there is no statistically significant difference between immunotherapy also chemotherapy for (Liver function tests) such as AST, ALT, ALP, TSB, and

BILD because their p-values (0.146, 0.522, 0.063, 0.354, and 0.215) are greater than =0.05, as shown in Table 4.5. According to Ma et al. [202], a united analysis of adverse event reports from patients through non-small cell lung tumor was performed to elucidate relationship between carboplatin and electrolyte imbalances. A total of 19901 contrary effects were reported by the FDA Adverse Event Reporting System "FAERS". receive. The pooled odds ratio (ROR) then ninety five percentages confidence interval (CI) show that carboplatin is hyponatremia (pooled ROR = 1.57, ninety five percentages CI 1.18-2.09, p = 1.99103) then hypokalemia (pooled). ROR = 2.37, ninety-five percentages) was shown to be significantly associated with related CI 1.80-3.10, p = 5.241010) compared to other treatments. Furthermore, dehydration is commonly associated through carboplatin treatment (pooled ROR = 2.01, ninety five percent CI 1.52-2.66, P = 8.37107), resulting in extreme water consumption and reduced blood electrolyte levels. I found. This information is not included in the FDA-accepted drug label but may support clarify the physiological processes of carboplatin-induced electrolyte imbalance. The above findings will help in the treatment and rapid elimination of life-threatening electrolyte imbalances during cancer treatment. On the other hand, compare to the electrolyte of research, there is no statistically significant difference between the mean of immunotherapy then chemotherapy for Na, K, and CI shown in Table 4.6 because of their p-values (0.201, 0.232, and 0.361) are higher than α=0.05 respectively.

According to Zhang et al [204], 1432 patients with small cell lung cancer (NSCLC) were included in six randomized controlled trials (RCTs), and the patients were treated with three PD1/PDL1 inhibitors (atezolizumab, nivolumab, and pembrolizumab). The group with high PDL1 expression had a substantially greater ORR than the group with low expression (0.35 [95 percent CI, 0.30–0.40] vs 0.11 [95 percent CI, 0.09–0.14]). The outcomes of the subgroup analysis, which was classified based on the kind of drugs and antibodies used to evaluate immune checkpoint inhibitors, were identical to the pooled outcome. Nonetheless, PDL1 activity was neither prognostic nor predictive of overall survival (OS) or progression-free survival (PFS) in patients treated through PD1/PDL1 inhibitors vs chemotherapy (PFS).

In our study, there is a statistically significant difference between the mean of immunotherapy and chemotherapy for PD1test based on (t=3.58, p-value=0.001). Figure 4.1 displays that the mean of chemotherapy (1.816) is smaller than the mean of immunotherapy (21.804). Nevertheless, there is no statistically significant difference between immunotherapy and chemotherapy for glucose, HBA1C, ACE and insulin serum since their p-values (0.139, 0.312, 0.540, and 0.060) are all more than =0.05.

According to Saar et al. [203], the clinicopathological features of the enrolled individuals. Amid 121 patients, 89 (74%) were men then thirty-two (26%) were ladies, with a mean age of sixty-seven years (range, 36 81 years). 56 patients (forty six percent) were diagnosed with

adenocarcinoma, whereas sixty-five patients (54 percent) were analyzed with squamous cell tumor. The vast common of the patients (79 percent) were present smokers.

Su et al. [199], PD1 / PDL1 immune checkpoint inhibition in NSCLC patients is more tolerable than conventional standard chemotherapy, even if the AEs of these agents differ from the AEs of conventional cell proliferation inhibitors. I am. Therefore, better management needs to better understand the side effects associated with these treatments. These unfavorable reactions affected many human tissues and organs, causing poisonous reactions ranging from slight malaise to simple and life-threatening liver then lung poisoning [115, 116]. Anti-PD1 / PDL1 AE was usually less severe, patients were relatively well tolerated and had lower mortality compared to standard chemotherapy. Nonetheless, the early onset of AE requires urgent medical attention, especially in older patients, and these toxic reactions need to be monitored more closely to minimize potential effects.

This study included twelve trials, 7.490 individuals, and nine therapeutic modalities, according to Liang et al [205]. Except for ocrelizumab in combination with chemotherapy (HR =0.72), all chemo immunotherapies outperformed chemotherapy in terms of prolonging OS then PFS in PDL1 expression nonselective individuals. The PDL1 receptor is found primarily in macrophages, antigen-presenting cells, B and T lymphocytes, epithelial, muscular, and endothelial cells, whereas the PD-1 receptor is found mostly inactivated cytotoxic T cells. Another goal of the study was to compare the level of PDL1 ligand expression and localization in NSCLC to that of commonly used diagnostic markers such as Ki-67 proliferation antigen, p63, and thyroid transcription factor 1 (TTF-1) proteins, which are used to differentiate morphologic subtypes of NSCLC [195].

Zhao et al. [206] this is the utmost complete assessment of studies investigating the suggestion between irAE then clinical outcome in NSCLC patients getting anti-PD1 antibodies. A mutual analysis of twenty six cohorts found a significant association between irAE prevalence and improved patient response and prognosis, as a predictor of the effectiveness of anti-PD1 remedy in NSCLC patients. Emphasized the usefulness of irAE. To our knowledge, this is the first and utmost wide-ranging systematic review, followed by a meta-analysis assessing the association between irAE incidence and clinical outcome after anti-PD1 antibody remedy with NSCLC.

6. CONCLUSION

To summarize, there is a statistically significant difference in the mean of immunotherapy against chemotherapy for the WBC test based on (t=-2.170, p-value=0.034). As demonstrated in Table 4.2, the mean of chemotherapy (14.677) is greater than the mean of immunotherapy (8.029). However, there is no statistically significant difference in the mean of immunotherapy against chemotherapy for Thyroid Function Test such as T3 (Triiodothyronine), T4 (Thyroxine), and TSH (Thyroid-stimulating hormone) since their p-values (0.875, 0.391 and 0.370, respectively) are more than =0.05. On the other hand, the renal Function Test shows a statistically significant difference among the mean of immunotherapy then chemotherapy for the urea test depending on (t=2.309, p-value=0.025). Table 4.4 reveal that the mean of chemotherapy (38.886) is greater than the mean of immunotherapy (28.497). Also, there is no statistically significant difference between the mean of immunotherapy then chemotherapy for creatinine because its p-value (0.318) is higher than α=0.05. Furthermore, there is no statistically significant difference between immunotherapy then chemotherapy for (liver function tests) such as AST, ALT, ALP, TSB, and BILD because their p-values (0.146, 0.522, 0.063, 0.354, and 0.215) are greater than =0.05, as revealed in Table 4.5.

In electrolyte, there is no statistically significant difference between the mean of immunotherapy and chemotherapy for Na, K, and Cl shown in Table 4.6 because their p-values (0.201, 0.232, and 0.361) are higher than α=0.05 respectively. Finally, other tests there are no statistical differences between mean immunotherapy and chemotherapy for glucose, HBA1C, ACE and insulin serum because their p-values (0.139, 0.312, 0.540, and 0.060) respectively. But also, there is a statistically significant difference between the mean of immunotherapy and chemotherapy for PD1test depending on (t=3.58, p-value=0.001). The mean of chemotherapy (1.816) is less than the mean of immunotherapy (21.804) as shown in figure 4.1.

Correlation and regression for immunotherapy for (dose, cycle, week duration) for the weak negative correlation between the independent variable (dose) and the dependent variable (K). Following the identification of a weak negative association between (dose tests) and (K) (0.49) by Pearson's correlation analysis, it is crucial to understand the prediction and effect rate of dose on K. The same table also shows the ANOVA table for testing the goodness of fit for the explanatory variable (Dose) on the response variable (K), suggesting that the model is appropriate (F=9.862 and P-Value =0.004)as seen in Table 4.8.

REFERENCES

[1] Smith, R.A., Andrews, K.S., Brooks, D., Fedewa, S.A., Manassaram-Baptiste, D., Saslow, D., Brawley, O.W., Wender, R.C. (2018). Cancer screening in the United States, 2018: A Review of Current American Cancer Society Guidelines and Current Issues in Cancer Screening, *CA: A Cancer Journal for Clinicians*, 68 (4), 297-316.

[2] Sanmamed, M.F., Chen, L. (2018). A Paradigm Shift in Cancer Immunotherapy: from Enhancement to Normalization, *Cell*, 175 (2), 313-326.

[3] Chen, J., Alduais, Y., & Chen, B. (2021). Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC. Cell transplantation, 30, 09636897211041587.

[4] Dermani, F.K., Samadi, P., Rahmani, G., Kohlan, A.K., Najafi, R. (2019). PD-1/PD-L1 Immune Checkpoint: Potential Target for Cancer Therapy, *Journal of Cellular Physiology*, 234 (2), 1313-1325.

[5] Wei, J., Long, Y., Guo, R., Liu, X., Tang, X., Rao, J., Yin, S., Zhang, Z., Li, M., He, Q. (2019). Multifunctional Polymeric Micelle-Based Chemo-Immunotherapy with İmmune Checkpoint Blockade for Efficient Treatment of Orthotopic and Metastatic Breast Cancer, *Acta Pharmaceutica Sinica B*, 9 (4), 819-831.

[6] Cousin, S., Italiano, A. (2016). Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities, *Clinical Cancer Research*, 22 (18), 4550-4555.

[7] Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., Zhang, J. (2020). Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer, *Frontiers in Oncology*, 1821.

[8] Callahan, M. K., Wolchok, J. D. (2013). At the bedside: CTLA-4-and PD-1-Blocking Antibodies in Cancer Immunotherapy, *Journal of Leukocyte Biology*, 94 (1), 41-53.

[9] Dotti, G. (2009). Blocking PD-1 in Cancer Immunotherapy, *Blood, The Journal of the American Society of Hematology*, 114 (8), 1457-1458.

[10] Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., Luo, S. (2019). Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4, *Molecular Cancer*, 18 (1), 1-14.

[11] Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., Kochan, G. (2018).The Intracellular Signalosome of PD-L1 in Cancer Cells, *Signal Transduction and Targeted Therapy*, 3 (1), 1-9.

[12] Bose, C.K. (2017). Immune Checkpoints, Their Control by Immunotherapy and Ovarian Cancer, *Contemporary Oncology*, 21 (3), 189.

[13] Xu, Y., Wan, B., Chen, X., Zhan, P., Zhao, Y., Zhang, T., Liu, H., Afzal, M.Z., Dermime, S.,G-Hochwald., S.N., Hofman, P., Borghaei, H., Lin, D., Lv, T., Song, Y. (2019). The Association of PD-L1 Expression with the Efficacy of Anti-PD-1/PD-L1 İmmunotherapy and Survival of Non-Small Cell Lung Cancer Patients: A Meta-Analysis of Randomized Controlled Trials, *Translational Lung Cancer Research*, 8 (4), 413.

[14] Chen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., Ding, L. (2020). Epigenetic Strategies Synergize with PD-L1/PD-1 Targeted Cancer Immunotherapies to Enhance Antitumor Responses, *Acta Pharmaceutica Sinica B*, 10 (5), 723-733.

[15] Qu, J., Mei, Q., Liu, L., Cheng, T., Wang, P., Chen, L., Zhou, J. (2021). The Progress and Challenge of anti-PD-1/PD-L1 Immunotherapy in Treating Non-Small Cell Lung Cancer. *Therapeutic Advances in Medical Oncology*,(13), 1758835921992968.

[16] Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Takayama, K. (2020). Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. *Journal of Clinical Medicine*, 9 (5), 1362.

[17] Globocan, W. H. O. (2012). estimated cancer incidence, mortality and prevelance worldwide in 2012.[Internet]. International Agency for Research in Cancer (IARC). 2012.Available on : <

https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012 >.

[18] World Health Organization(WHO)(2009) World Health Organization Cancer fact sheet Available on: < https://www.who.int/news-room/fact-sheets/detail/cancer >.

[19] Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., Wong, K.K. (2014). Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases, *Nature Reviews Cancer*, 14 (8), 535-546.

[20] Siegel, R., Ma, J., Zou, Z., Jemal, A. (2014). Cancer Statistics, *CA: A Cancer Journal for Clinicians*, 64 (1), 9-29.

[21] Mak, K.S., Van Bommel, A. C., Stowell, C., Abrahm, J. L., Baker, M., Baldotto, C. S., Baldwin, D.R., Borthwick, D., Carbone, D.P., Chen, A.B., Fox, J., Haswell, T., Koczywas, M., Kozower, B.D., Mehran, R.J., Schramel, F.M., Senan, S., Stirling, R.G., Meerbeeck, J.P., Wouters, M.W.J.M., Peake, M.D., Peake, M.D. (2016). Defining a Standard Set of Patient-Centred Outcomes for Lung Cancer, *European Respiratory Journal*, 48 (3), 852-860.

[22] Ashley, L., Jones, H., Thomas, J., Newsham, A., Downing, A., Morris, E., Brown, J., Velikova, G., Forman, D., Wright, P. (2013). Integrating Patient Reported Outcomes with Clinical Cancer Registry Data: A Feasibility Study of the Electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) System, *Journal of Medical Internet Research*, 15 (10), e230.

[23] Tanvetyanon, T., Robinson, L. A., Schell, M. J., Strong, V. E., Kapoor, R., Coit, D. G., & Bepler, G. (2008). Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Available on: < https://www.ncbi.nlm.nih.gov/books/NBK75273/ > .

[24] Al-Shafa, F., Arifin, A. J., Rodrigues, G. B., Palma, D. A., & Louie, A. V. (2019). A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead?. Frontiers in Oncology, Vol.9, pp: 1-6.

[25] Weichselbaum, R. R., & Hellman, S. (2011). Oligometastases revisited. Nature reviews Clinical oncology, 8(6), 378-382.

[26] Eberhardt, W. E., De Ruysscher, D., Weder, W., Le Péchoux, C., De Leyn, P., Hoffmann, H., Westeel, V., Stahel, R., Felip, E., Peters, S., Members, P. (2015). 2nd ESMO Consensus Conference in Lung Cancer: Locally Advanced Stage III Non-Small-Cell Lung Cancer, *Annals of Oncology*, 26 (8), 1573-1588.

[27] De Ruysscher, D., Wanders, R., van Baardwijk, A., Dingemans, A.M.C., Reymen, B., Houben, R., Ollers, M., Lambin, P., Ruysscher, D.D. (2012). Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450), *Journal of Thoracic Oncology*, 7 (10), 1547-1555.

[28] Gomez, D.R., Blumenschein J., G.R., Lee, J.J., Hernandez, M., Ye, R., Camidge, D.R., Doebele, R.C., Skoulidis, F., Gaspar, L.E., Gibbons, D.L., Karam, J.A., Kavanagh, B.D., Tang, C., Heymach, J.V. (2016). Local Consolidative Therapy Versus Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer without Progression After First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study, *The Lancet Oncology*, 17 (12), 1672-1682.

[29] Iyengar, P., Wardak, Z., Gerber, D.E., Tumati, V., Ahn, C., Hughes, R.S., Dowell, J.E., Cheedella, N., Nedzi, L., Westover, K.D., Pulipparacharuvil, S., Choy, H., Timmerman, R.D. (2018). Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial, *JAMA Oncology*, 4 (1), e173501.

[30] Dingemans, A.M.C., Hendriks, L.E., Berghmans, T., Levy, A., Hasan, B., Faivre-Finn, C., Giaj Levra, M., Giaj Levra, N., Girard, N., Greillier, L., Lantuejoul, S., Edwards, J., Obrien, M., Reck, M., Smit, E.F., Schil, P.V., Postmus, P.E., Ramella, S., Lievens, Y., Gaga, M., Peled, N., Scagliotti, G.V., Senan, S., Paz Ares, L., Guckenberger, M., Mcdonald, F., Ekman, S., Cufer, T., Gietema, H., Infante, M., Dziadziuszko, R., Peters, S., Porta, R.R., Vansteenkiste, J., Dooms, C., Ruysscher, D., Besse, B., Novello, S. (2019). Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer A Consensus Report, *Journal of Thoracic Oncology*, 14 (12), 2109-2119.

[31] Duma, N., Santana-Davila, R., Molina, J.R. (2019). Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment, *In Mayo Clinic Proceedings*, 94 (8), 1623-1640.

[32] Malvezzi, M., Bertuccio, P., Levi, F., La Vecchia, C., Negri, E. (2012). European Cancer Mortality Predictions for the Year 2012, *Annals of Oncology*, 23 (4), 1044-1052.

[33] Siegel R.L, Miller K.D, Jemal A. (2018) Cancer Statistics, *CA: A Cancer Journal for Clinicians*, 68 (1), 7-30.

[34] Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W.E., Nicholson, A.G., Groome, P., Mitchell, A., Bolejack, V. (2016). The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, *Journal of Thoracic Oncology*, 11 (1), 39-51.

[35] Alberg, A.J., Samet, J.M. (2003). Epidemiology of Lung Cancer. *Chest*, 123 (1), 21-49.

[36] Lorigan, P., Radford, J., Howell, A., Thatcher, N. (2005). Lung Cancer After Treatment for Hodgkin's Lymphoma: A Systematic Review, *The Lancet Oncology*, *6*(10), 773-779.

[37] Sartorius, B., & Sartorius, K. (2016). How much incident of lung cancer was missed globally in 2012? An ecological country-level study. Geospatial Health, Vol.11,pp. 110-118.

[38] Cruz, C.S.D., Tanoue, L.T., Matthay, R.A. (2011). Lung cancer: Epidemiology, Etiology, and Prevention, *Clinics in Chest Medicine*, 32 (4), 605-644.

[39] Kohler, B.A, Ward, E., McCarthy, B.J, Schymura, M.J., Ries, L.A.G., Eheman, C., Cemal, A., Anderson, R.N., Ajani, U.A., Erwards, B.K. (2011) Annual Report to the Nation on the Status of Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous System, *Journal of the National Cancer Institute*, 103 (9), 714-736.

[40] Wakelee, H.A., Chang, E.T., Gomez, S.L., Keegan, T.H., Feskanich, D., Clarke, C.A., Holmberg, L., Yong, L.C., Kolonel, L.N., Gould, M.K., West, D.W. (2007). Lung Cancer Incidence in Never-Smokers, *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 25 (5), 472.

[41] Jia, Y., Yun, C. H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Eck, M. J. (2016). Overcoming EGFR (T790M) and EGFR (C797S) Resistance with Mutant-Selective Allosteric Inhibitors, *Nature*, 534 (7605), 129-132.

[42] Rolfo, C., Mack, P.C., Scagliotti, G.V., Baas, P., Barlesi, F., Bivona, T.G., Herbest, R.S., Mok, T.S., Peled, N., Pirker, R., Raez, L.E., Reck, M., Riess, J.W., Sequist, L.V., Shepherd, F.A., Sholl, L.M., Tan, D.S.W., Wakelee, H.A., Wistuba, I.I., Wynes, M.W., Carbone, D.P., Hirsch, F.A., Gandara, D.R. (2018). Liquid Biopsy for Advanced non-small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC, *Journal of Thoracic Oncology*, 13 (9), 1248-1268.

[43] Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo Jack, I., Gadgeel, S., Schultz, K., Singh, M., Chin, E., Parks, M., Lee, D., Dicecca, R.H., Lockerman, E., Huynh, T., Logan, J., Ritterhouse, L.L., Le, L.P., Muniappan, A., Digumarthy, S., Channick, C., Keyes, C., Getz, G., Dias Santagata, D., Heist, R.S., Lennerz, J., Sequist, LV., Benes, C.H.., Lafrate, A.J., Mino Kenudson, M., Engalman, J.A., Shaw, A. T. (2016). Molecular Mechanisms of Resistance to First and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer, *Cancer Discovery*, 6 (10), 1118-1133.

[44] Goldstraw, P., Crowley, J.J. (2006). The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer, *Journal of Thoracic Oncology*, 1 (4), 281-286.

[45] Rami-Porta, R., Ball, D., Crowley, J., Giroux, D.J., Jett, J., Travis, W.D., Tsuboi, M., Vallieres, E., Goldstraw, P. (2007). The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer, *Journal of Thoracic Oncology*, 2 (7), 593-602.

[46] Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P.E., Rusch, V., Sobin, L. (2007). The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, *Journal of Thoracic Oncology*, 2 (8), 706-714.

[47] Asamura, H., Chansky, K., Crowley, J., Goldstraw, P., Rusch, V.W., Vansteenkiste, J.F., Watanabe, H., Wu, Y.L., Zielnski, M., Ball, D., Rami-Porta, R. (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for lung Cancer, *Journal of Thoracic Oncology*, *10*(12), 1675-1684.

[48] Chassagnon, G., Bennani, S., Revel, M.P. (2017). Nouvelle Classification TNM des Cancers du Poumon Non à Petites Cellules, *Revue de Pneumologie Clinique*, 73 (1), 34-39.

[49] Mountain, C.F., Dresler, C.M. (1997). Regional lymph node Classification for Lung Cancer Staging, *Chest*, 111 (6), 1718-1723.

[50] Asamura, H., Suzuki, K., Kondo, H., Tsuchiya, R. (2000). Where is the Boundary Between N1 and N2 Stations in Lung Cancer?. *The Annals of Thoracic Surgery*, 70 (6), 1839-1846.

[51] Fujimoto, T., Cassivi, S.D., Yang, P., Barnes, S.A., Nichols, F.C., Deschamps, C., Allen, M., Pairolero, P.C. (2006). Completely Resected N1 Non–Small Cell Lung Cancer: Factors Affecting Recurrence and Long-Term Survival, *The Journal of Thoracic and Cardiovascular Surgery*, 132 (3), 499-506.

[52] Greene, F.L., Balch, C.M., Fleming, I.D., Fritz, A., Haller, D.G., Morrow, M., Page, D.L. (2002). AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors, *Springer Science & Business Media*.

[53] Saji, H., Tsuboi, M., Shimada, Y., Kato, Y., Yoshida, K., Nomura, M., Matsubayashi, H., Nagao, T., Kakihana, M., Usuda, J., Kajiwara, N., Ohira, T., Ikeda, N. (2013). A Proposal for Combination of Total Number and Anatomical Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer, *Chest*, 143 (6), 1618-1625.

[54] Wei, S., Asamura, H., Kawachi, R., Sakurai, H., Watanabe, S.I. (2011). Which is the Better Prognostic Factor for resected non-small cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification?. *Journal of Thoracic Oncology*, 6 (2), 310-318.

[55] Bria, E., Milella, M., Sperduti, I., Alessandrini, G., Visca, P., Corzani, F., Giannarelli, D., Cerasoli, V., Cuppone, F., Cecere, F.L., Marchetti, A., Saccof, R., Mucillif, F., Malatesta, S., Guettif, L., Vitalef, L., Ceribelli, A., Rinaldi, M., Terzoli, E., Cognetti, F., Facciolo, F. (2009). A Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer, *Lung Cancer*, 66 (3), 365-371.

[56] Darling, G.E., Allen, M.S., Decker, P.A., Ballman, K., Malthaner, R.A., Inculet, R.I., Jones, D.R., Meckenna, R.J., Landreneau, R.J., Butnam, J.B. (2011). Number of Lymph Nodes Harvested from a mediastinal Lymphadenectomy: Results of the Randomized, Prospective American College of Surgeons Oncology Group Z0030 Trial, *Chest*, 139 (5), 1124-1129.

[57] Liu, H., Yan, T., Zhang, T., Chen, X., Wang, Y., Du, J. (2019). Proposal of a New Nodal Classification for Operable Non-Small Cell Lung Cancer Based on the Number of Negative Lymph Nodes and the Anatomical Location of Metastatic Lymph Nodes, *Medicine*, 98 (20).

[58] Brambilla, E., Travis, W.D. (2014) Lung Cancer, World Cancer Report.

[59] Siegel, R.L., Miller, K.D., Fedewa, S.A., Ahnen, D.J., Meester, R.G., Barzi, A., Jemal, A. (2017). Colorectal Cancer Statistics, 2017. *CA: A Cancer Journal for Clinicians*, 67 (3), 177-193.

[60] Little, A.G., Rusch, V.W., Bonner, J.A., Gaspar, L.E., Green, M.R., Webb, W.R., Stewart, A.K. (2006). Patterns of Surgical Care of Lung Cancer Patients, The Annals of Thoracic Surgery, 80 (6), 2051-2056.

[61] Fry, W.A., Phillips, J.L., Menck, H.R. (1999). Ten-Year Survey of Lung Cancer Treatment and Survival in Hospitals in the United States: A National Cancer Data Base Report, *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 86 (9), 1867-1876.

[62] Detterbeck, F.C., Boffa, D.J., Tanoue, L.T. (2009). The New Lung Cancer Staging System, *Chest*, 136 (1), 260-271.

[63] Nagasaka, M., Gadgeel, S.M. (2018). Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer, *Expert Review of Anticancer Therapy*, 18 (1), 63-70.

[64] Ruiz-Cordero, R., Devine, W.P. (2020). Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer, *Surgical Pathology Clinics*, 13 (1), 17-33.

[65] Friedlaender, A., Banna, G., Malapelle, U., Pisapia, P., Addeo, A. (2019). Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where are We Today?. *Frontiers in Oncology*, 9, 166.

[66] Relli, V., Trerotola, M., Guerra, E., Alberti, S. (2019). Abandoning the Notion of non-Small Cell Lung Cancer, *Trends in Molecular Medicine*, 25 (7), 585-594.

[67] Imyanitov, E.N., Iyevleva, A.G., Levchenko, E.N. (2020). Molecular Testing and Targeted Therapy for Non-Small Cell Lung Cancer: Current Status and Perspectives. *Critical Reviews in Oncology/Hematology*, 103194.

[68] Nakamura, H., Saji, H. (2014). A Worldwide Trend of Increasing Primary Adenocarcinoma of the Lung, *Surgery Today*, 44 (6), 1004-1012.

[69] Moiseyenko, V.M., Procenko, S.A., Levchenko, E.V., Barchuk, A.S., Moiseyenko, F.V., Iyevleva, A.G., Mitiushkina, N.V., Togo, A.V., Semionov, I.I., Ivantsov, A.O., Matsko, D.E., Imyanitov, E.N. (2010). High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma, *Oncology Research and Treatment*, 33 (5), 231-238.

[70] Sokolenko, A.P., Imyanitov, E.N. (2018). Molecular Diagnostics in Clinical Oncology, *Frontiers in Molecular Biosciences*, *5*, 76.

[71] Nadal, E., Massuti, B., Dómine, M., García-Campelo, R., Cobo, M., Felip, E. (2019). Immunotherapy with Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Insights from Long-Term Survivors, *Cancer Immunology, Immunotherapy*, *68*(3), 341-352.

[72] Zhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., Chen, G., Zhao, J., He, J., Wu, F., Zou, J., Zhu, X., Lin, X. (2020). Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study, *Journal of Clinical Oncology*, 38 (24), 2753-2761.

[73] Kaderbhaï, C. G., Coudert, B., Bertaut, A., Adnet, J., Favier, L., Lagrange, A., Casasnovas, P., Mettey, L., THarin, Z., Foucher, P., Martin, E. (2020). Outcomes of Concurrent Radiotherapy with Weekly Docetaxel and Platinum-Based Chemotherapy in Stage III Non-Small-Cell Lung Cancer, *Cancer/Radiothérapie*, 24 (4), 279-287.

[74] Jemal, A., Thun, M. J., Ries, L.A., Howe, H.L., Weir, H.K., Center, M.M., Ward, E., Wu, X.C., Eheman, C., Anderson, R., Ajani, U.E., Kohler, B., Edwards, B.K. (2008). Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco use, and Tobacco Control, *JNCI: Journal of the National Cancer Institute*, 100 (23), 1672-1694.

[75] Mason, K., Staab, A., Hunter, N., McBride, W., Petersen, S., Terry, N., Milas, L. (2001). Enhancement of Tumor Radioresponse by Docetaxel: Involvement of Immune System, *International Journal of Oncology*, 18 (3), 599-606.

[76] Mudad, R., Ramsey, M., Kovitz, K., Curiel, T.J., Hartz, R., Nedzi, L.L., Weiner, R.S., Zakris, E.L. (2003). Concomitant Weekly Docetaxel, Cisplatin and Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: A Dose Finding Study, *Lung Cancer*, 39 (2), 173-177.

[77] Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., Adjei, A.A. (2008). Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment and Survivorship. *In Mayo Clinic Proceedings*, 83 (5), 584-594.

[78] Van Meerbeeck, J.P. (2001). Staging of Non-Small Cell Lung Cancer: Consensus, Controversies and Challenges, *Lung Cancer*, 34, S95-S107.

[79] Santana-Davila, R., Devisetty, K., Szabo, A., Sparapani, R., Arce-Lara, C., Gore, E.M., Moran, A., Williams, C.D., Kelley, M.C., Whittle, J. (2015). Cisplatin and Etoposide Versus Carboplatin and Paclitaxel with Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An analysis of Veterans Health Administration Data, *Journal of Clinical Oncology*, 33 (6), 567.

[80] Vansteenkiste, J., De Ruysscher, D., Eberhardt, W.E.E., Lim, E., Senan, S., Felip, E., Peters, S. (2013). Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up, *Annals of Oncology*, 24, 89-98.

[81] Steuer, C.E., Behera, M., Ernani, V., Higgins, K.A., Saba, N.F., Shin, D.M., Pakkala, S., Pillai, R.N., Owonikoko, T.K., Curran, W.J., Belani, C.P., Khuri, F.R., Ramalingam, S.S. (2017). Comparison of Concurrent use of Thoracic Radiation with Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients with Stage iii Non–Small-Cell Lung Cancer: A Systematic Review, *JAMA Oncology*, 3 (8), 1120-1129.

[82] Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H.C., Paulus, R., Yamanaka, T., Bozonnat, M.C., Uitterhoeve, A., Wang, X., Stewart, L., Arriagada, R., Burdett, S., Pignon, J. P. (2010). Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer, *Journal of Clinical Oncology*, 28 (13), 2181-2190.

[83] Wang, L., Wu, S., Ou, G., Bi, N., Li, W., Ren, H., Cao, J., Liang, J., Li, J., Zhou, Z., Lv, J., Zhang, X. (2012). Randomized Phase II Study of Concurrent Cisplatin/Etoposide or Paclitaxel/Carboplatin and Thoracic Radiotherapy in Patients with Stage III Non-Small Cell Lung Cancer, *Lung Cancer*, 77 (1), 89-96.

[84] Vokes, E.E., Herndon, J.E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J.N., Watson, D.M., Akerley, W., Green, M. R. (2007). Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B, *Journal of Clinical Oncology*, 25 (13), 1698-1704.

[85] Creane, C.B., Seymour, S., Colucci, C., Mothersill, M. (1999). Radiobiological Effects of Docetaxel (Taxotere): A Potential Radiation Sensitizer, *International Journal of Radiation Biology*, 75 (6), 731-737.

[86] Wu, H.G., Bang, Y.J., Choi, E.K., Ahn, Y.C., Kim, Y.W., Lim, T.H., Suh, C., Park, K., Park, C.I. (2002). Phase I Study of Weekly Docetaxel and Cisplatin Concurrent with Thoracic Radiotherapy in Stage III Non-Small-Cell Lung Cancer, *International Journal of Radiation Oncology, Biology, Physics*, 52 (1), 75-80.

[87] Segawa, Y., Kiura, K., Takigawa, N., Kamei, H., Harita, S., Hiraki, S., Watanabe, Y., Sugimoto, K., Shibayama, T., Yonei, T., Ueoka, H., Takemoto, M., Kanazawa, S., Takata, I., Nogami, N., Hotta, K., Hiraki, A., Tabata, M., Matsuo, K., Tanimoto, M., Tanimoto, M. (2010). Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy with Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy with Concurrent Thoracic Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: OLCSG 0007, *Journal of Clinical Oncology*, 28 (20), 3299-3306.

[88] Ahn, J.S., Ahn, Y.C., Kim, J.H., Lee, C.G., Cho, E.K., Lee, K.C., Chen, M., Kim, D.W., Kim, H.K., Min, YJ, Kang, J.H., Choi, J.H., Kim, S.W, Zhu, G., Wu, Y.L., Kim, S.R., Lee, K.H., Song, H.S., Choi, Y.L., Sun, J.M., Jung, S.H., Ahn, M.J., Park, K. (2015). Multinational Randomized Phase III Trial with or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04, *Journal of Clinical Oncology*, *33*(24), 2660-2666.

[89] Herbst, R. S., Morgensztern, D., Boshoff, C. (2018). The Biology and Management of Non-Small Cell Lung Cancer, *Nature*, 553 (7689), 446-454.

[90] Siegel, R., Naishadham, D., Jemal, A. (2012) Cancer Statistics, *CA Cancer Journal of Clinical*, 62, 10-29.

[91] Bradley, J., Hu, C., Komaki, R.R., Masters, G.A., Blumenschein, G.R., Schild, S.E., Bogart, J.A., Forster, K.M., Magliocco, A.M., Kavadi, V.S., Narayan, S., Iyengar, P., Robinson, C.G.,Wynn, R.B., Koprowski, R.P., Olson, M.R., Meng, J., Paulus, R., Curran, W.C., Choy, H. (2020). Long-Term Results of NRG Oncology RTOG 0617: Standard-Versus High-Dose Chemoradiotherapy with or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer, *Journal of Clinical Oncology*, 38 (7), 706-714.

[92] Giaj-Levra, N., Borghetti, P., Bruni, A., Ciammella, P., Cuccia, F., Fozza, A., Franceschini, D., Scotti, V., Vagge, S., Alongi, F. (2020). Current Radiotherapy Techniques in NSCLC: Challenges and Potential Solutions. *Expert Review of Anticancer Therapy*, 20 (5), 387-402.

[93] Auperin, A., Le Pechoux, C., Pignon, J. P., Koning, C., Jeremic, B., Clamon, G., Einhorn, l., Ball, D., Trovo, M.G., Groen, H.J.M., Bonner, J.A., Chevalier, T., Arriagada, R. (2006). Concomitant Radio-

Chemotherapy Based on Platin Compounds in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis of Individual Data from 1764 Patients, *Annals of Oncology*, 17 (3), 473-483.

[94] Timmerman, R., Paulus, R., Galvin, J., Michalski, J., Straube, W., Bradley, J., Fakiris, A., Bezjal, A., Videtic, G., Johnstone, D., Fowler, J., Gore, E., Choy, H. (2010). Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer, *Jama*, 303 (11), 1070-1076.

[95] Videtic, G.M., Donington, J., Giuliani, M., Heinzerling, J., Karas, T. Z., Kelsey, C.R., Lally, B.E., Latzka, K., Lo, S.S., Moghanaki, D., Movsas, B., Rimner, A., Roach, M., Rodrigues, G., Shirvani, S.M., Simone, C.B., Timmerman, R., Daly, M. E. (2017). Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: Executive Summary of an ASTRO Evidence-Based Guideline, *Practical Radiation Oncology*, 7 (5), 295-301.

[96] Louie, A.V., Palma, D.A., Dahele, M., Rodrigues, G.B., Senan, S. (2015). Management of Early-Stage Non-Small Cell Lung Cancer Using Stereotactic Ablative Radiotherapy: Controversies, İnsights, and Changing Horizons, *Radiotherapy and Oncology*, 114 (2), 138-147.

[97] McAleese, J., Baluch, S., Drinkwater, K. (2015). The Quality of Curative-Intent Radiotherapy for Non-Small Cell Lung Cancer in the UK, *Clinical Oncology*, 27 (9), 498-504.

[98] Walters, S., Maringe, C., Coleman, M.P., Peake, M.D., Butler, J., Young, N., Bergstrom, S., Hanna, L., Jakobsen, E., Kölbeck, K., Sundstrom, S., Engholm, G., Gavin, A., Gjerstroff, M.L., Hatcher, J., Johannesen, T.B., Linklater, K.M., Mcghan, C.E., Steward, J., Tracey, E., Turner, D., Richards, M.A., Rachet, B. (2013). Lung Cancer Survival and Stage at Diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: A Population-Based Study, 2004–2007. *Thorax*, 68 (6), 551-564.

[99] Ohri, N., Shen, X., Dicker, A.P., Doyle, L.A., Harrison, A.S., Showalter, T.N. (2013). Radiotherapy Protocol Deviations and Clinical Outcomes: A Meta-Analysis of cooperative group Clinical Trials, *Journal of the National Cancer Institute*, 105 (6), 387-393.

[100] Prewett, S.L., Aslam, S., Williams, M.V., Gilligan, D. (2012). The Management of Lung Cancer: a UK Survey of Oncologists, *Clinical Oncology*, 24 (6), 402-409.

[101] Goss, C.H., Mayer-Hamblett, N., Aitken, M.L., Rubenfeld, G.D., Ramsey, B.W. (2004). Association Between Stenotrophomonas Maltophilia and Lung Function in Cystic Fibrosis, *Thorax*, 59 (11), 955-959.

[102] Rulach, R., McLoone, P., Lumsden, G., McKay, S., MacLaren, V., Macphee, J., Moore, K., Omand, M., Sproule, M., Currie, S., Aitken, A., Ferguson, R., Valentine, R., Houston, P., Harrow, S., Hicks, J. (2020). Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-Small Cell Lung Cancers Using 50 Gy in Five Fractions, *Clinical Oncology*, 32 (4), 250-258.

[103] Haasbeek, C.J.A., Palma, D., Visser, O., Lagerwaard, F.J., Slotman, B., Senan, S. (2012). Early-Stage Lung Cancer in Elderly Patients: A Population-Based Study of Changes in Treatment Patterns and Survival in the Netherlands, *Annals of Oncology*, 23 (10), 2743-2747.

[104] Ball, D., Mai, G. T., Vinod, S., Babington, S., Ruben, J., Kron, T., Chesson, B., Herschtal, A., Vanevski, M., Rezo, A., Elder, C., Skala, M., Wirth, A., Wheeler, G., Lim, A., Shaw, M., Schofield, P., Irving, L., Solomon, B.L., Le, H. (2019). Stereotactic Ablative Radiotherapy Versus Standard Radiotherapy in Stage 1 Non-Small-Cell Lung Cancer (TROG 09.02 CHISEL): A Phase 3, Open-Label, Randomised Controlled Trial, *The Lancet Oncology*, 20 (4), 494-503.

[105] Bezjak, A., Paulus, R., Gaspar, L.E., Timmerman, R.D., Straube, W.L., Ryan, W.F., Garces, Y.I., Pu, A.T., Singh, A.K., Videtic, G.M., McGarry, R.C., Iyengar, P., Pantarotto, J.R., Urbanic, J.J., Sun, A.Y., Daly, M.E., Grills, I.S., Sperduto, P., Normolle, D.P., Bradley, J.D., Choy, H. (2019). Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial, *Journal of Clinical Oncology*, 37 (15), 1316.

[106] Tekatli, H., Haasbeek, N., Dahele, M., De Haan, P., Verbakel, W., Bongers, E., Hashemi, S., Nossent, E., Spoelstra, F., Langen, A.J., Slotman, B., Senan, S. (2016). Outcomes of hypofractionated high-Dose Radiotherapy in Poor-Risk Patients With "Ultracentral" Non–Small Cell Lung Cancer, *Journal of Thoracic Oncology*, 11 (7), 1081-1089.

[107] Koshy, M., Malik, R., Weichselbaum, R.R., Sher, D.J. (2015). Increasing Radiation Therapy Dose is Associated with İmproved Survival in Patients Undergoing Stereotactic Body Radiation Therapy for Stage I Non–Small-Cell Lung Cancer, *International Journal of Radiation Oncology, Biology, Physics*, 91 (2), 344-350.

[108] Senthi, S., Haasbeek, C.J., Slotman, B.J., Senan, S. (2013). Outcomes of Stereotactic Ablative Radiotherapy for Central Lung Tumours: A Systematic Review, *Radiotherapy and Oncology*, 106 (3), 276-282.

[109] Postmus, P.E., Kerr, K.M., Oudkerk, M., Senan, S., Waller, D.A., Vansteenkiste, J., Escriu, C., Peters, S. (2017). Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up, *Annals Oncology*, 28 (4), iv1–iv21.

[110] Adebahr, S., Collette, S., Shash, E., Lambrecht, M., Le Pechoux, C., Faivre-Finn, C., Ruysscher, D.D., Peulen, H., Belderbos, J., Fink, C., Guckenberger, M., Hurkmans, C., Nestle, U. (2015). LungTech, an EORTC Phase II Trial of Stereotactic Body Radiotherapy for Centrally Located Lung Tumours: A Clinical Perspective, *The British Journal of Radiology*, 88 (1051), 20150036.

[111] Adebahr, S., Liu, Y., Colette, S., Faivre-Finn, C., Ahmad, S., Ahmed, M., Belderbos, J., Andratschke, K., Geets, X., Guckenberger, M., Konopa, K., Lambrecht, M., Lewitzki, V., Lievens, Y., Pourel, N., Ruysscher, D., Dziadziuszko, R., Fortpied, C., Mcdonald, F., Peulen, H., Grosu, A., Hurkmans, C., Le Pechoux, C., Nestle, U. (2019). EORTC 22113-8113 Lungtech Trial on SBRT of Central Lung Tumors, *Radiotherapy and Oncology*, S24-S25.

[112] Mountain, C.F. (2000). The International System for Staging Lung Cancer, *In Seminars in Surgical Oncology*, 18 (2), 106-115.

[113] Sawabata, N., Miyaoka, E., Asamura, H., Nakanishi, Y., Eguchi, K., Mori, M., Nomori, H., Fujii, Y., Okumura, M., Yokoi, K. (2011). Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in 2004: Demographic and Prognosis Changes Over Decade, *Journal of Thoracic Oncology*, 6 (7), 1229-1235.

[114] Vansteenkiste, J., Van Damme, V., Dooms, C. (2010). Generalized or Personalized Treatment for Stage IIIA-N2 Non-Small-Cell Lung Cancer?. *Expert Opinion on Pharmacotherapy*, 11 (10), 1605-1609.

[115] O'Rourke, N., Figuls, M.R., Bernadó, N.F., Macbeth, F. (2010). Concurrent Chemoradiotherapy in Non-Small Cell Lung Cancer, *Cochrane Database of Systematic Reviews*, 16 (6), CD002140.

[116] Shien, K., Toyooka, S. (2016). Role of Surgery in N2 NSCLC: Pros, *Japanese Journal of Clinical Oncology*, 46 (12), 1168-1173.

[117] Bryan, D.S., Donington, J.S. (2019). The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer, *Current Treatment Options in Oncology*, 20 (4), 1-13.

[118] Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi III, A. T., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R.B., Feins, R.H., Gandara, D.R., Fry, W.A., Darling, G., Johnson, D.H., Green, M.R., Miller, R.C., Ley, J., Sause, W.T., Cox, J. D. (2009). Radiotherapy Plus Chemotherapy with or Without Surgical Resection for Stage III Non-Small-Cell Lung Cancer: A Phase III Randomised Controlled Trial, *The Lancet*, 374 (9687), 379-386.

[119] Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., Jemal, A. (2015). Global Cancer Statistics, 2012. *CA: A Cancer Journal for Clinicians*, 65 (2), 87-108.

[120] De Angelis, R., Sant, M., Coleman, M.P., Francisci, S., Baili, P., Pierannunzio, D., Trama, A., Visser, O., Brenner, H., Ardanaz, E., Bielska-Lasota, M., Engholm, G., Nennecke, A., Siesling, S., Berrino, F., Cappocaccia, R., Eurocare-5 Working Group. (2014). Cancer Survival in Europe 1999–2007 by Country and Age: Results of EUROCARE-5-a Population-Based Study, *The Lancet Oncology*, 15 (1), 23-34.

[121] Decatris, M. P., O'Byrne, K. J. (2016). Immune Checkpoint Inhibitors as First-Line and Salvage Therapy for Advanced Non-Small-Cell Lung Cancer, *Future Oncology*, 12 (15), 1805-1822.

[122] Grulich, A.E., Van Leeuwen, M.T., Falster, M.O., Vajdic, C.M. (2007). Incidence of Cancers in People with HIV/AIDS Compared with Immunosuppressed Transplant Recipients: A Meta-Analysis, *The Lancet*, 370 (9581), 59-67.

[123] Thomas, J. A., Badini, M. (2011). The Role of Innate Immunity in Spontaneous Regression of Cancer, *Indian Journal of Cancer*, 48 (2), 246.

[124] Vansteenkiste, J., Craps, J., De Brucker, N., Wauters, I. (2015). Immunotherapy for Non-Small-Cell Lung Cancer: The Past 10 Years, *Future Oncology*, 11 (19), 2681-2695.

[125] Kirkwood, J.M., Tarhini, A.A. (2009). Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy, *Journal of Clinical Oncology*, 27 (16), 2583-2585.

[126] Decatris, M., Santhanam, S., O'Byrne, K. (2002). Potential of Interferon-α in Solid Tumours, *BioDrugs*, 16 (4), 261-281.

[127] Gahr, S., Stoehr, R., Geissinger, E., Ficker, J.H., Brueckl, W.M., Gschwendtner, A., Gattnloehner, S., Fuchs, F.S., Schulz, C., Rieker, R.J., Hartmann, A., Ruemmele, P., Dietmaier, W. (2013). EGFR Mutational Status in a Large Series of Caucasian European NSCLC Patients: Data from Daily Practice, *British Journal of Cancer*, 109 (7), 1821-1828.

[128] Soo, R.A., Lim, S.M., Syn, N.L., Teng, R., Soong, R., Mok, T.S., Cho, B.C. (2018). Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: Current Controversies and Future Directions, *Lung Cancer*, *115*, 12-20.

[129] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P. Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Muñoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L. (2012). Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial, *The Lancet Oncology*, 13 (3), 239-246.

[130] Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S.S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Jun Zhang, M.L., You, C. (2011). Erlotinib Versus Chemotherapy As First-Line Treatment for patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (Optimal, Ctong-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study, *The Lancet Oncology*, 12 (8), 735-742.

[131] Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T. (2010). Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR, *New England Journal of Medicine*, 362 (25), 2380-2388.

[132] Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., Fukuoka, K., West Japan Oncology Group. (2010). Gefitinib Versus Cisplatin Plus Docetaxel in Patients with Non-Small-Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial, *The Lancet Oncology*, 11 (2), 121-128.

[133] Sequist, L.V., Yang, J.C.H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Sequist, L.V., Yang, J.C.H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S.L., Orlov, S., Tsai, C.M., Boyer, M., Su, W.C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K.H., Shah, R., Massey, D., Zazulina, V., Shahidi, M., Schuler, M. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients with Metastatic Lung Adenocarcinoma with EGFR Mutations, *Journal of Clinical Oncology*, 31 (27), 3327-3334.

[134] Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Masuti, B., Palmero, R., Carcere, P.A., Pless, M., Popat, S., Kotsakis, A., Cuffe, S., Bidoli, P., Favaretto, A., Froesch, P., Reguart, N., Puente, J., Coate, Barlesi, F., Rauch, D., Thomas, M., Camps, C., Gomez-Codina, J.,

Majem, M., Porta, R., Shah, R., Hanrahan, E., Kammler, R., Pharm, B.R., Rabaglio, M., Kassapian, M., Karachaliou, N., Tam, R., Shames, D.S., Molina-Vila, M.A., Stanel, R.A. (2017). Erlotinib and Bevacizumab in Patients with Advanced Non-Small-Cell Lung Cancer and Activating EGFR Mutations (Belief): An International, Multicentre, Single-Arm, Phase 2 Trial, *The Lancet Respiratory Medicine*, 5 (5), 435-444.

[135] Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., Nagase, S., Okamoto, I., Yamanaka, T., Tajima, K., Harada, R., Fukuoka, M., Yamamoto, N. (2014). Erlotinib Alone or with Bevacizumab as First-Line Therapy in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harbouring EGFR Mutations (JO25567): an open-label, randomised, multicentre, Phase 2 Study, *The Lancet Oncology*, 15 (11), 1236-1244.

[136] Hanahan, D., Weinberg, R.A. (2011). Hallmarks of Cancer: The Next Generation, *Cell*, 144 (5), 646-674.

[137] Leach, D.R., Krummel, M.F., Allison, J.P. (1996). Enhancement of Antitumor İmmunity by CTLA-4 Blockade, *Science*, 271 (5256), 1734-1736.

[138] Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., Massard, C., Fuerea, A., Ribrag, V., Gazzah, A., Armand, J.P., Amellal, N., Angevin, E., Noel, N., Boutros, C., Mateus, C, Robert, C., Soria, J.C., Marabelle, A., Lambotte, O. (2016). Immune Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review, *European Journal of Cancer*, 54, 139-148.

[139] Alsaab, H.O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S.K., Iyer, A.K. (2017). PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations and Clinical Outcome, *Frontiers in Pharmacology*, (8), 561.

[140] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert,C., Schadendorf, D., Hassel, J.C., Akerley, W., Alfons, J.M., Eertwegh, V., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbé, C., Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A., Urba, W.J. (2010). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, *New England Journal of Medicine*, 363 (8), 711-723.

[141] Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., Brahmer, J.R., Lawrence, D.P., Atkins, M.B., Powderly, J.D., Leming, P.D., Lipson, E.J., Puzanov, E.J., Puzanov, I., Smith, D.C., Taube, J.M., Wigginton, J.M., Kollia, G.D., Gupta, A., Pardoll, D.M., Sosman, J.A., Hodi, F.S. (2014). Survival, Durable Tumor Remission, and Long-Term Safety in Patients with Advanced Melanoma Receiving Nivolumab, *Journal of Clinical Oncology*, 32 (10),1020.

[142] Mahoney, K.M., Rennert, P.D., Freeman, G. J. (2015). Combination Cancer Immunotherapy and New Immunomodulatory Targets, *Nature Reviews Drug Discovery*, 14 (8), 561-584.

[143] Sun, Z., Fourcade, J., Pagliano, O., Chauvin, J.M., Sander, C., Kirkwood, J.M., Zarour, H.M. (2015). IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells, *Cancer Research*, 75 (8), 1635-1644.

[144] Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., Freeman, G.J. (2007). Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses, *Immunity*, 27 (1), 111-122.

[145] Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M. (2016). Mechanism-Driven Biomarkers to Guide immune Checkpoint Blockade in Cancer Therapy, *Nature Reviews Cancer*, 16 (5), 275-287.

[146] Schreiber, R.D., Old, L.J., Smyth, M.J. (2011). Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, *Science*, 331 (6024), 1565-1570.

[147] Liede, A., Hernandez, R.K., Wade, S.W., Bo, R., Nussbaum, N.C., Ahern, E., Dougall, W.C., Smyth, M.J. (2018). An Observational Study of concomitant Immunotherapies and Denosumab in Patients with advanced Melanoma or Lung Cancer, *Oncoimmunology*, 7 (12), e1480301.

[148] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C.U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., Ribas, A. (2015).

Pembrolizumab Versus Ipilimumab in Advanced Melanoma, *New England Journal of Medicine*, 372 (26), 2521-2532.

[149] Goldberg, S.B., Gettinger, S.N., Mahajan, A., Chiang, A.C., Herbst, R.S., Sznol, M., Tsiouris, A.J., Cohen, J., Jilaveanu, L., Yu, J., Hedge, U., Speaker, S., Madura, M., Ralabate, A., Rivera, A., Rowen, E., Gerrish, H., Yao, X., Chiang, V., Kluger, H.M. (2016). Pembrolizumab for Patients with Melanoma or Non-Small-Cell Lung Cancer and Untreated brain metastases: Early Analysis of a Non-Randomised, Open-Label, Phase 2 Trial, *The Lancet Oncology*, 17 (7), 976-983.

[150] Davis, F.G., Dolecek, T.A., McCarthy, B.J., Villano, J.L. (2012). Toward Determining the Lifetime Occurrence of Metastatic Brain Tumors Estimated from 2007 United States Cancer İncidence Data, *Neuro-Oncology*, 14 (9), 1171-1177.

[151] Gavrilovic, I.T., Posner, J.B. (2005). Brain Metastases: Epidemiology and Pathophysiology, *Journal of Neuro-Oncology*, 75 (1), 5-14.

[152] Mathieu, D., Kondziolka, D., Cooper, P. B., Flickinger, J. C., Niranjan, A., Agarwala, S., ... & Lunsford, L. D. (2007). Gamma knife radiosurgery for malignant melanoma brain metastases. *Clinical Neurosurgery*, Vol. 54, pp. 241.

[153] Yushak, M.L., Chiang, V.L., Kluger, H.M. (2015). Clinical Trials in Melanoma Patients with Brain Metastases, *Pigment Cell Melanoma Res*earch, 28, 741–43.

[154] Reck, M. (2018). Pembrolizumab as First-Line Therapy for Metastatic non-Small-Cell Lung Cancer, *Immunotherapy*, 10 (2), 93-105.

[155] Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimitrakopoulou, V.A., Patnaik, A., Powell, S.F., Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimitrakopoulou, V.A., Patnaik, A., Powell, S.F., Gentzler, R.D., Martins, R.G., Stevenson, J.P., Jalal, S.I., Panwalkar, A., Yang, J.C.H., Gubens, M., Sequist, L.V., Awad, M.M., Fiore, J., Ge, Y., Raftopoulos, H., Gandhi, L. (2016). Carboplatin and Pemetrexed with or without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label Keynote-021 Study, *The Lancet Oncology*, 17 (11), 1497-1508.

[156] Hui, R., Garon, E.B., Goldman, J.W., Leighl, N.B., Hellmann, M.D., Patnaik, A., Gandhi, L., Eder, J.P., Ahn, M.J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G.M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N.A. (2017). Pembrolizumab as First-Line Therapy for Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial, *Annals of Oncology*, 28 (4), 874-881.

[157] Zhou, Z.J., Zhan, P., Song, Y. (2015). PD-L1 Over-Expression and Survival in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis, *Translational Lung Cancer Research*, Vol.4 (2), pp203-208.

[158] Roach, C., Zhang, N., Corigliano, E., Jansson, M., Toland, G., Ponto, G., Dolled-Filhart, M., Emancipator, K., Stanforth, D., Kulangara, K. (2016). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-Cell Lung Cancer, *Applied Immunohistochemistry & Molecular Morphology*, 24 (6),392.

[159] Hirsch, F.R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Hirsch, F.R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., Mistry, A., Kalamegham, R., Averbuch, S., Novotny, J., Rubin, E., Emancipator, K., McCaffery, I., Williams, A., Walker, J., Longshore, J., Tsao, M.S., Kerr, K.M. (2017). PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project, *Journal of Thoracic Oncology*, 12 (2), 208-222.

[160] Nguyen, L.T., Ohashi, P.S. (2015). Clinical Blockade of PD1 and LAG3—Potential Mechanisms of Action, *Nature Reviews Immunology*, 15 (1), 45-56.

[161] Kwok, G., Yau, T.C., Chiu, J.W., Tse, E., Kwong, Y.L. (2016). Pembrolizumab (Keytruda), *Human Vaccines & Immunotherapeutics*, 12 (11), 2777-2789.

[162] Topalian, S.L., Drake, C.G., Pardoll, D.M. (2015). Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, *Cancer Cell*, 27 (4), 450-461.

[163] Finkelmeier, F., Waidmann, O., Trojan, J. (2018). Nivolumab for the Treatment of Hepatocellular Carcinoma, *Expert Review of Anticancer Therapy*, 18 (12), 1169-1175.

[164] Pardoll, D.M. (2012). The Blockade of Immune Checkpoints in Cancer Immunotherapy, *Nature Reviews Cancer*, 12 (4), 252-264.

[165] Fridman, W.H., Pages, F., Sautes-Fridman, C., Galon, J. (2012). The Immune Contexture in Human Tumours: Impact on Clinical Outcome, *Nature Reviews Cancer*, 12 (4), 298-306.

[166] Gajewski, T.F., Schreiber, H., Fu, Y.X. (2013). Innate and Adaptive Immune Cells in the Tumor Microenvironment, *Nature Immunology*, 14 (10), 1014-1022.

[167] Medler, T.R., Cotechini, T., Coussens, L.M. (2015) Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance, *Trends Cancer*, 1, 66–75.

[168] Patel, S.P., Kurzrock, R. (2015). PD-L1 Expression As a predictive Biomarker in Cancer Immunotherapy, *Molecular Cancer Therapeutics*, 14 (4), 847-856.

[169] Prat, A., Navarro, A., Paré, L., Reguart, N., Galván, P., Pascual, T., Martinez, A., Nurciforo, P., Comerma, L., Alos, L., Pardo, N., Cedres, S., Fan, C., Parker, J.S., Gaba, L., Victoria, I., Vinolas, N., Vivancos, A., Arance, A., Felip, E. (2017). Immune Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma and Melanoma, *Cancer Research*, 77 (13), 3540-3550.

[170] Ribas, A., Robert, C., Hodi, F.S., Wolchok, J.D., Joshua, A.M., Hwu, W.J., Weber, J.S., Zarour, H.M., Kefford, R., Loboda, A., Albright, A., Kang, S.P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunnceford, J.K., McClanahan, T., Ayers, M., Daud, A. (2015). Association of Response to Programmed Death Receptor 1 (PD-1) Blockade with Pembrolizumab (MK-3475) with An Interferon Inflammatory Immune Gene Signature, *Journal of Clinical Oncology*, 33(15).

[171] Wang, C., Thudium, K.B., Han, M., Wang, X.T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M., Srinivasan, M., Singh, S., Wong, S., Garner, N., Leblnac, H., Bunch, R.T., Blanset, D., Selby, M.J., Korman, A.J. (2014). In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and İn Vivo Toxicology in Non-Human Primates, *Cancer Immunology Research*, *2* (9), 846-856.

[172] Guo, L., Zhang, H., Chen, B. (2017). Nivolumab As Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor, *Journal of Cancer*, 8 (3),410.

[173] Ciccarese, C., Alfieri, S., Santoni, M., Santini, D., Brunelli, M., Bergamini, C., Licitra, L., Montironi, S., Tortora, G., Massari, F. (2016). New Toxicity Profile for Novel Immunotherapy Agents: Focus on Immune-checkpoint Inhibitors, *Expert Opinion on Drug Metabolism & Toxicology*, 12 (1), 57-75.

[174] Haanen, J.B.A.G., Carbonnel, F., Robert, C., Kerr, K.M., Peters, S., Larkin, J., Jordan, K. (2017). Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up, *Annals of Oncology*, Vol. 28, pp.iv119-iv142.

[175] Brahmer, J.R., Lacchetti, C., Schneider, B.J., Atkins, M.B., Brassil, K.J., Caterino, J.M., Chau, I., Ernstoff, M.S., Gardner, J.M., Ginex, P., Hallmeyer, S., Chakrabarty, J.H., Leighl, N.B., Mammen, J.S., McDermott, D.F., Naing, A., Nastoupil, L.J., Phillips, T., Porter, L.D., Puzanov, I., Reichner, C.A., Santomasso, B.D., Seigel, C., Spira, A., Suarez-Almazor, M.E., Wang, Y., Weber, J.S., Wolchok, J.D. Thompson, J.A. (2018). Management of Immune Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, *36* (17),1714.

[176] Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M.E., LeBoeuf, N.R., Lenihan, D., Onofrei, C., Shannon, V., Sharma, R., Silk, A.W., Skondra, D., Suarez-Almazor, M.E., Wang, Y., Wiley, K., Kaufman, H.L., Ernstoff, M.S. (2017). Managing Toxicities Associated with Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, *Journal for Immunotherapy of Cancer*, 5 (1), 1-28.

[177] Girotra, M., Hansen, A., Farooki, A., Byun, D.J., Min, L., Creelan, B.C., Callahan, M.K., Atkins, M.K., Sharon, E., Antonia, S.J., West, P., Gravell, A.E. (2018). The Current Understanding of the

Endocrine Effects from immune Checkpoint Inhibitors and Recommendations for Management, *JNCI Cancer Spectrum*, 2 (3), pky021.

[178] Cappelli, L.C., Gutierrez, A.K., Bingham III, C.O., Shah, A.A. (2017). Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature, *Arthritis Care & Research*, 69 (11), 1751-1763.

[179] Khoja, L., Day, D., Chen, T.W. W., Siu, L.L., Hansen, A.R. (2017). Tumour and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review, *Annals of Oncology*, 28 (10), 2377-2385.

[180] Bocquet-Tremoureux, S., Scharbarg, E., Nguyen, J.M., Varey, E., Quereux, G., Saint-Jean, M., Peuvrel, L., Khammari, A., Dreno, B. (2019). Efficacy and Safety of Nivolumab in Metastatic Melanoma: Real-World Practice, *European Journal of Dermatology*, 29 (3), 315-321.

[181] Arheden, A., Skalenius, J., Bjursten, S., Stierner, U., Ny, L., Levin, M., Jespersen, H. (2019). Real-World Data on PD-1 Inhibitor Therapy in Metastatic Melanoma, *Acta Oncologica*, 58 (7), 962-966.

[182] Parakh, S., Randhawa, M., Nguyen, B., Warburton, L., Hussain, M.A., Cebon, J., Milward, M., Yip, D., Ali, S. (2019). Real World Efficacy and Toxicity of Combined Nivolumab and Ipilimumab in Patients with Metastatic Melanoma, *Asia-Pacific Journal of Clinical Oncology*, 15 (1), 26-30.

[183] Lala, V., Goyal, A., Bansal, P., Minter, D.A. (2020). Liver Function Tests, *StatPearls [Internet]*.

[184] Gounden, V., Jialal, I. (2018). Renal Function Tests, *Treasure Island*,Available on :

< https://europepmc.org/article/NBK/nbk507821 >. .

[185] Shahinian, V.B., Bahl, A., Niepel, D., Lorusso, V. (2017). Considering Renal Risk while Managing Cancer, *Cancer Management and Research*, (*9)*,167.

[186] Luo, J., Chen, Y. J., Chang, L.J. (2012). Fasting Blood Glucose Level and Prognosis in Non-Small Cell Lung Cancer (NSCLC) Patients, *Lung Cancer*, 76 (2), 242-247.

[187] Ezzeldin, N., Dıyaa, A., Ezzeldin, H., Hussein, A., Farouk, H., Kandil, D. (2012). A Study of the Relationship Between the Blood Levels of the 8-Oxoguanine DNA Glycosylase, Smoking and Risk of Lung Cancer, *The Medical Journal of Cairo University*, 80 (2) 495-499.

[188] Kong, M., Lim, Y.J. (2021). Hemoglobin A1c Level is a Prognostic Factor for Locoregional Recurrence in Stage III Non-Small Cell Lung Cancer Patients Treated with Radiotherapy, *Thoracic Cancer*, 12 (22), 3032–3038.

[189] Petridou, E.T., Sergentanis, T.N., Antonopoulos, C.N., Dessypris, N., Matsoukis, I.L., Aronis, K., Efremidis, A., Syrigos, C., Mantzoros, C.S. (2011). Insulin Resistance: an Independent Risk Factor for Lung Cancer?, *Metabolism*, 60 (8), 1100-1106.

[190] Cappuzzo, F., Tallini, G., Finocchiaro, G., Wilson, R. S., Ligorio, C., Giordano, L., Toschi, L., Incarbone, M., Cavina, R., Terracciano, L., Roncalli, M., Alloisio, M., Varella-Garcia, M., Franklin, W.A., Santoro, A. (2010). Insulin-Like Growth Factor Receptor 1 (IGF1R) Expression and Survival in Surgically Resected Non-Small-Cell Lung Cancer (NSCLC) Patients, *Annals of Oncology*, 21 (3), 562-567.

[191] Dziadziuszko, R., Camidge, D. R., Hirsch, F.R. (2008). The Insulin-Like Growth Factor Pathway in Lung Cancer, *Journal of Thoracic Oncology*, 3 (8), 815-818.

[192] Morgillo, F., Kim, W.Y., Kim, E.S., Ciardiello, F., Hong, W.K., Lee, H.Y. (2007). Implication of the Insulin-Like Growth Factor-IR Pathway in the Resistance of Non–Small Cell Lung Cancer Cells to Treatment with Gefitinib, *Clinical Cancer Research*, 13 (9), 2795-2803.

[193] Argirion, I., Weinstein, S.J., Männistö, S., Albanes, D., Mondul, A.M. (2017). Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Lung Cancer, *Cancer Epidemiology and Prevention Biomarkers*, 26 (10), 1519-1524.

[194] Jiang, J., Ren, H.Y., Geng, G.J., Mi, Y.J., Liu, Y., Li, N., Yang, S.Y., Shen, D.Y. (2018). Oncogenic Activity of Insulin in the Development of Non-Small Cell Lung Carcinoma, *Oncology Letters*, 15 (1), 447-452.

[195] Pawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dzieiel, P., Nowinska, K. (2019). Role of PD-L1 Expression in Non-Small Cell Lung Cancer and their Prognostic Significance According to Clinicopathological Factors and Diagnostic Markers, *International Journal of Molecular Sciences*, 20(4),824.

[196] Shukuya, T., Carbone, D.P. (2016). Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer, *Journal of Thoracic Oncology*, 11 (7), 976-988.

[197] Medjebar, S., Truntzer, C., Perrichet, A., Limagne, E., Fumet, J.D., Richard, C., Elkrief, A., Rutin, B., Rebe, C., Ghiringhelli, F. (2020). Angiotensin Converting Enzyme (ACE) Inhibitor Prescription Affects Non-Small-Cell Lung Cancer (NSCLC) Patients Response to PD-1/PD-L1 Immune Checkpoint Blockers, *Oncoimmunology*, 9 (1), 1836766.

[198] Rojko, L., Megyesfalvi, Z., Czibula, E., Reiniger, L., Teglasi, V., Szegedi, Z., Szallasi, Z., Dome, B., Moldvay, J. (2020). Longitudinal Analysis of Complete Blood Count Parameters in Advanced-Stage Lung Cancer Patients, *Thoracic Cancer*, 11 (11), 3193-3204.

[199] Su, S., Li, T., Lu, B., Wang, X., Li, J., Chen, M., Lu, Y., Bai, Y., Hu, Y., Ouyang, W., Ma, Z., Li, Q., Li, H., Wang, Y. (2015). Three Dimensional Radiation Therapy to the Primary Tumor with Concurrent Chemotherapy in Patients with Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study from PPRA-RTOG, China, *International Journal of Radiation Oncology, Biology, Physics*, 93 (4), 769-777.

[200] Pabla, N., Dong, Z. (2008). Cisplatin Nephrotoxicity: Mechanisms and Renoprotective Strategies, Kidney International, 73 (9), 994–1007.

[201] Kim, J., Cho, C. K., Yoo, H.S. (2016). Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy, *Integrative Cancer Therapies*, 15 (4), 467-477.

[202] Ma, Y., Hou, L., Yu, F., Lu, G., Qin, S., Xie, R., Yang, H., Wu, T., Luo, P., Chai, L., Lv, Z., Peng, X., Wu, C., Fu, D. (2017). Incidence and Physiological Mechanism of Carboplatin Induced Electrolyte Abnormality Among Patients with Non-Small Cell Lung Cancer, *Oncotarget*, 8 (11), 18417.

[203] Saar, M., Narits, J., Mägi, L., Aaspõllu, H., Vapper, A., Kase, M., ... & Jaal, J. (2021). Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase. *Molecular and clinical oncology*,*15*(4), 1-8.

[204] Zhang, B., Liu, Y., Zhou, S., Jiang, H., Zhu, K., Wang, R. (2020). Predictive effect of PD-L1 Expression for Immune Checkpoint Inhibitor (PD-1/PD-L1 Inhibitors) Treatment for Non-Small Cell Lung Cancer: A Meta-Analysis, *International Immunopharmacology*, 80, 106214.

[205] Liang, H., Lin, G., Wang, W., Huang, J., Yang, Y., Lan, Y., Wang, R., Cui, F., Hao, Z., Deng, H., Zhao, S., Cheng, B., Xiong, S., Li, J., Li, C., Liu, J., He, J., Liang, W. (2020). Feasibility and safety of PD-1/L1 İnhibitors for Non-Small Cell Lung Cancer in Front-Line Treatment: A Bayesian Network Meta-Analysis, *Translational Lung Cancer Research*, 9 (2),188.

[206] Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., Chen, X. (2021). Immune-Related Adverse Events Associated with Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*,3723.

CURRICULUM VITAE

Barran Yousif MIKAEEL

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]